Methods for Treating and Preventing Multiple Sclerosis

ABSTRACT

We have discovered that LRG-47 (also called p47 GTPase), plays a central role in the pathogenesis of multiple sclerosis, and that inhibition of LRG-47 activity by anti-LRG-47 antibodies or of LRG-47 expression by siRNA dramatically reduce the pathology and symptoms of multiple sclerosis. Certain embodiments of the invention are directed to the therapeutic use of anti-LRG-47 antibodies (mouse or rabbit or other antibodies that are humanized or human antibodies to LRG-47, preferably antibodies made against human LRG-47) or siRNA or antisense nucleotides that specifically hybridize with the gene or mRNA or cDNA encoding human LRG-47 to treat or prevent multiple sclerosis and other autoimmune diseases that are T-cell-mediated. Other embodiments are directed to methods for the diagnosis of multiple sclerosis or to determining the aggressiveness of multiple sclerosis by determining the amount of human LRG-47 or LRG-47 mRNA in a biological sample from the patient.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a national phase application of PCTApplication No. PCT/US2008/062158, filed on May 1, 2008, and claimspriority to Provisional Appln. 60/915,127, filed May 1, 2007, the entirecontents of which are hereby incorporated by reference as if fully setforth herein, under 35 U.S.C. §119(e).

STATEMENT OF GOVERNMENTAL INTEREST

This invention was made with Government support under US Public HealthService grant NO: NINDS 042855). The Government has certain rights inthe invention.

REFERENCE TO SEQUENCE LISTING SUBMITTED VIA EFS-WEB

This application includes an electronically submitted sequence listingin .txt format. The .txt file contains a sequence listing entitled“2016-05-06 15003-032US1_ST25.txt” created on May 6, 2016 and is 11,077bytes in size. The sequence listing contained in this .txt file is partof the specification and is hereby incorporated by reference herein inits entirety.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention is in the field of methods and pharmaceuticalcompositions for treating or preventing Multiple Sclerosis,Encephalitis, and other autoimmune diseases that are associated with anabnormal increase in the number of activated T-cells.

2. Description of the Related Art

Multiple sclerosis (MS) is a severe, chronic disabling disease thataffects approximately 1 out of every 1,600 people. The majority of theaffected individuals develop symptoms as young adults between 20 and 40years of age, with roughly 60% of the cases occurring in women. Thedisease is characterized by neuron deterioration in the central nervoussystem (CNS) with the associated loss of the insulating myelin sheathfrom around the axons of the nerve cells, referred to as demyelination.The disease presents itself in the white matter of the brain and spinalcord as a number of sclerotic lesions or plaques (Prineas (1985)Demyelinating Diseases, Elsvevier: Amsterdam; Raine (1983) MultipleSclerosis, Williams and Wilkins: Baltimore; Raine et al. (1988) J.Neuroimmunol. 20:189-201; and Martin (1997) J. Neural Transmission(Suppl) 49:53-67). The characteristic MS lesion is inflamed, exhibitsaxonal demyelination, axonal degeneration, and is found around smallvenules. These characteristics typically evolve early in plaquedevelopment and are hypothesized to occur as a result of a breakdown inthe blood-brain barrier (BBB). As a consequence of BBB breakdown,infiltrates consisting of various lymphocytes and macrophages enter thebrain or spinal cord. This inflammatory infiltrate ultimately leads toaxonal degeneration and scar tissue formation, and in many instances, isassociated with incomplete remyelination (Martin (1997) J. NeuralTransmission (Suppl) 49:53-67). Further, it is hypothesized that thisapparent immunologic attack targets not only the myelin sheath, but alsothe oligodendrocytes imperative to CNS myelin production. As a result,not only is the nerve-insulating myelin damaged, but the ability ofoligodendroglial cells to repair damaged myelin is seriously compromised(Scientific American 269 (1993):106-114). Development of multiple areasof scar tissue (sclerosis) along the covering of the nerve cells slowsor blocks the transmission of nerve impulses in the affected area,resulting in the development of the symptoms characteristic of MS. Thesesymptoms include pain and tingling in the arms and legs; localized andgeneralized numbness, muscle spasm and weakness; difficulty with balancewhen standing or walking; difficulty with speech and swallowing;cognitive deficits; fatigue; and bowel and bladder dysfunction.

Approximately half of the people with this disease suffer fromrelapsing-remitting MS. In these cases, the afflicted individualexperiences repeated unpredictable attacks, due to episodes ofinflammation, axonal demyelination, axonal degeneration, and developmentof glial scar tissue. These attacks are separated by periods ofremission, during which the symptoms stabilize or diminish. Acuteneurological deficits occur with each attack, and in many cases, theaccumulation of residual deficits as a result of these attackseventually leads to worsening disability and impairment in quality oflife. Approximately 30-40% of the afflicted population have chronicprogressive MS (either primary or secondary) in which neurologicaldeterioration occurs in the absence of clinically apparent attacks.Recently, immunomodulatory therapy with interferon-beta (IFN-beta) hasproven to be successful in reducing the severity of the underlyingdisease in patients with relapsing-remitting MS. FDA-approved IFN-betatherapies for the treatment of relapsing-remitting MS in the UnitedStates include interferon beta-la (marketed as Avonex®, available fromBiogen, Inc.) and interferon-beta-1b (marketed as Betaseron®, availablefrom Chiron Corporation). Both of these therapeutic agents are partiallyeffective in reducing the frequency and severity of relapses, slowingthe rate of disease progression, or reducing the degree of braininflammation as measured by a variety of magnetic resonance imaging(MRI) techniques.

MS is considered to be a T cell-mediated autoimmune disease of the brainand spinal cord [Traugott et al. 1983; Vizler et al. 1999]. The failedapoptosis of auto-reactive T cells has been implicated in MSpathogenesis. While there appears to be a localized CNS immune response,peripheral immune cell abnormalities appear to correlate with centraldisease activity [Hafler and Weiner 1989] and may precede MRI activity.Apoptosis is an important mechanism in immune system regulation,responsible for elimination of autoreactive T-lymphocytes (T cells),B-lymphocytes (B cells) and monocytes from the circulation andprevention of their entry into the CNS [Mahoney and Rosen 2005; Todaroet al. 2004]. It has been hypothesized that a genetic predispositionexists in MS patients whereby a failure of autoreactive T cells and Bcells as well as activated macrophages to undergo apoptosis contributesto the pathogenesis of MS [Bernard and Derosbo 1992; Pender 1998; Penderand Rist 2001].

Prescribing decisions seem to be driven by evidence-based medicine and arecent report by the American Association of Neurologists (Goodin D S etal; Neurology Jan. 22, 2002; 58(2):169-78) is a key document. Theconsensus amongst many neurologists is that early, aggressive therapywith beta-interferons was desirable in increasing the time to firstrelapse and limiting the overall disease load, although it wasrecognized that there was no evidence that this approach showedlong-term benefit on EDSS score (a measure of disease-relateddisability). There is currently no satisfactory diagnostic marker formultiple sclerosis. There is therefore a need for new diagnostic methodsand for new disease-modifying therapies for MS.

SUMMARY OF THE INVENTION

A certain embodiment of the invention is directed to a method fortreating or preventing multiple sclerosis (or another autoimmunedisease) in a patient, by administering a therapeutically effectiveamount of an isolated anti-, antibody or biologically active fragmentthereof. The isolated antibody can be the polyclonal anti-human LRG-47antibody 138AB made in our laboratory and described herein, or afragment or variant thereof, preferably a humanized form. Wherever afragment of an antibody is mentioned herein it is understood that thisfragment is a biologically active fragment or variant of the antibody.The antibody can also be a monoclonal, polyclonal, chimeric, humanizedor bispecific anti-LRG-47 antibody or humanized antibody selected fromthe group comprising LRG-47 (A-19) Antibody, LRG-47 (M-95) Antibody,LRG-47 (M-16) Antibody, and LRG-47 (P-20) Antibody, anti-human LRG-47138AB or fragment or variant thereof.

Another embodiment is directed to a method for treating or preventingmultiple sclerosis (or another autoimmune disease) in a patient, byadministering a therapeutically effective amount of a compound thatdecreases expression of human LRG-47. The compound can be an antisensenucleic acid or siRNA that is sufficiently complementary to the humangene or mRNA encoding LRG-47 to hybridize to it thereby forming a stableduplex.

Another embodiment is directed to a method for treating or preventingmultiple sclerosis (or another autoimmune disease) in a patient, by a.determining a pre-treatment level of human LRG-47 protein in apre-treatment biological sample taken from the animal, b. administeringan amount of a compound that reduces human LRG-47 expression levels inanimal cells (the above described siRNA or antisense nucleotide), c.determining a post-treatment level of human LRG-47 protein in apost-treatment biological sample taken from the animal, d. comparing thepre-treatment and post-treatment levels of LRG-47 protein in therespective biological samples, and e. determining that treatment iseffective if the post-treatment level of LRG-47 is significantly lowerthan the pre-treatment level. This method optionally further includesthe step f. if the difference between the pre-treatment andpost-treatment levels of LRG-47 are not significantly different, thenincreasing the amount or frequency of administration of the compounduntil the post-treatment level of LRG-47 is significantly lower than thepre-treatment level. A similar method can be used for an autoimmunedisease.

A biological sample for the purpose of the present inventions can be anerve sample, serum, blood, plasma, cerebral spinal fluid, fibroblasts,leukocytes, skin, or urine.

Another embodiment is directed to method for diagnosing a patient who isat risk of developing multiple sclerosis, by a. determining the level ofhuman LRG-47 protein in a biological sample taken from the patient andin a corresponding sample taken from a control subject that is notaffected with multiple sclerosis, b. comparing the level of LRG-47protein in the biological samples and forming a diagnosis that thepatient is at risk of developing multiple sclerosis if the level ofLRG-47 protein in the patient sample is significantly higher than thelevel of LRG-47 protein in the control sample. A similar diagnosticmethod can be used to diagnose a patient at risk of developing anautoimmune disease. The method can have the further step of c.determining that the patient has multiple sclerosis if the patient showsother objective or subjective indicia of multiple sclerosis.

Another embodiment is directed to a method for determining theprogression of multiple sclerosis, by a. determining the level of humanLRG-47 protein in a first biological sample taken from the patient at afirst time, b. determining the level of LRG-47 protein in a secondbiological sample taken from the patient at a second later time, c.comparing the level of LRG-47 protein in the first and second biologicalsamples and diagnosing progression of multiple sclerosis if the level ofLRG-47 protein in the second sample is significantly higher than thelevel of LRG-47 protein in the first sample. A similar method can beused to determine the progression of an autoimmune disease.

Another embodiment is directed to a method for determining if a patientis responding to treatment for MS, by a. determining the level of humanLRG-47 protein in a first biological sample taken from the patient at afirst time, b. determining the level of LRG-47 protein in a secondbiological sample taken from the patient at a second later time, c.comparing the level of LRG-47 protein in the first and second biologicalsamples and determining that the patient is responding to treatment ifthe level of LRG-47 protein in the second sample is significantly lowerthan the level of LRG-47 protein in the first sample.

Another embodiment is directed to the new anti-human LRG-47 antibody138AB and a fragment thereof, preferably a humanized form of theantibody, and to a pharmaceutical composition that includes theanti-human LRG-47 antibody 138AB or humanized fragment. Anotherembodiment is directed to a pharmaceutical composition that includes ahumanized isolated anti-LRG-47 antibody or fragment thereof selectedfrom the group including LRG-47 (A-19) Antibody, LRG-47 (M-95) Antibody,LRG-47 (M-16) Antibody, and LRG-47 (P-20) Antibody.

Another embodiment is directed to a diagnostic kit for determining thepresence of human LRG-47 protein or human LRG-47 mRNA in a biologicalsample including: a) a) a vessel or vessels for receiving a blood, serumor CSF or cell sample from the subject; b) an agent that specificallydetects LRG-47 protein or amplifies LRG-47 mRNA; and c) printedinstructions for detecting the LRG-47 protein or the amplified LRG-47mRNA in the sample. The agent that specifically detects LRG-47 proteincan be an isolated anti-LRG-47 antibody selected from the groupincluding LRG-47 (A-19) Antibody, LRG-47 (M-95) Antibody, LRG-47 (M-16)Antibody, LRG-47 (P-20) Antibody, and anti-human LRG-47 138AB Antibody,preferably humanized.

DESCRIPTION OF THE DRAWINGS

The present invention is illustrated by way of example, and not by wayof limitation, in the figures of the accompanying drawings.

FIGS. 1A-1E. Expression of LRG-47 in EAE mice. FIG. 1A and FIG. 1B:Total RNA was isolated from spinal cords of naïve, CFA (completeFreund's adjuvant)-treated and MBP-induced EAE mice. Quantitative realtime PCR (FIG. 1A) shows transcripts of mouse LRG-47 in spinal cordtissues from each group on day 14 after induction of EAE (in theMBP-treated group; peak symptoms). * P<0.001, n=3-5 mice/group. FIG. 1B:Northern analysis of spinal cord tissue for LRG-47 transcripts. Timepoints indicate days after immunization with MBP-derived peptide. FIG.1C: Quantification of Northern blot images. * P<0.001, N=3/group. FIG.1D and FIG. 1E: Effect of gene deletion of LRG-47 on EAE. (FIG. 1D)LRG-47 hemizygous (LRG-47^(+/−)), homozygous (LRG-47^(−/−)) mice, and WTlittermates (LRG-47^(+/+)) were immunized with 1-9NAc MBP-derivedpeptide. Symptoms were assessed according to a clinical scoring system(*P<0.01 vs. LRG^(−/−) mice). FIG. 1E: Lower panel, representative H &E-stained spinal cord sections from EAE-induced mice of the indicatedgenotype (LRG-47^(+/+), LRG-47^(+/−), and LRG-47^(−/−)) on day 21. Upperpanel, analysis of area occupied by nuclei from samples derived from theabove groups of mice (FIG. 1B-FIG. 1D). * P<0.01, n=3-4/group.

FIGS. 2A-2G. LRG-47^(−/−) mice display reduced accumulation and enhancedapoptosis of activated CD4 T-cells in the CNS during EAE. FIG. 2A:Infiltrating cells were isolated from the CNS of LRG-47^(−/−) mice andWT littermates on day 18-20 (peak symptomatic EAE, clinical score 3-4,in WT animals). Infiltrating cells isolated from the CNS wereimmunostained with antibodies to CD4 conjugated with PerCP, CD44conjugated with PE, or Annexin V conjugated with FITC. FACS analyseswere used to determine the percentage of cells staining positively foreach of the markers, CD4, CD44^(hi), and annexin V. CD44^(hi) andannexin V were gated for CD4. * P<0.05, n=3-5/group. FIG. 2B: FACSanalysis of activated CD4 T-cells isolated from lymph nodes of miceinduced to develop EAE with MBP. Lymphocytes isolated from lymph nodesof LRG^(−/−) mice and WT littermates were stained with anti-CD4conjugated with PerCP and CD44 conjugated with PE. The percentage ofCD44^(hi)-positive cells was determined by FACS gated for CD4 cells.*P<0.01, n=3-5/group. FIG. 2C: Lymphocytes in lymph nodes from EAE micewere subjected to TUNEL staining. TUNEL-positive cells were quantitatedusing UNIVERSAL image software. FIG. 2D: In vivo proliferation of CD4⁺T-cells isolated from mice induced to develop EAE. Mononuclear cellsisolated from the CNS were stained with anti-CD4 PerCP and anti-BrdUfollowed by FACS analysis. Cells were pooled from 5 mice of each group.BrdU incorporation was expressed as the percentage of BrdU-positive CD4⁺T-cells gated in CD4⁺ T-cells. FIG. 2E, FIG. 2F, FIG. 2G: Effect ofLRG-47 gene deletion on T-cell proliferation and apoptosis of CD4T-cells in response to MBP: in vitro studies. FIG. 2E: ³H-thymidineincorporation was performed on lymphocytes and splenocytes isolated fromthe indicated mice on day 7 after immunization in the presence of MBP(2.5 μg/ml). * P<0.01 vs. other groups of mice, n=3-5/group. FIG. 2F:Splenocytes from LRG-47^(−/−) and WT littermates were stained withanti-CD4 conjugated to PE and annexin V conjugated to FITC afterstimulation with MBP (2.5 μg/ml) for 48 and 72 hrs, respectively. FACSanalyses show the percentage of annexin-positive cells gated in the CD4⁺T-cell population. FIG. 2G: TUNEL-positive CD4 T-cells followingexposure to MBP. CD4 T-cells isolated from spleens of LRG^(−/−) and WTmice were incubated with MBP (2.5 μg/ml) for 48 hours and subjected toTUNEL staining. #P<0.05, *P<0.01, n=3-5/group.

FIGS. 3A-3I. Expression and translocation of LRG-47 in encephalitogenicCD4 T-cell (1AE10) and its effect on cell proliferation and apoptosis.FIG. 3A: Northern blotting of 1AE10 cells shows elevated levels ofLRG-47 transcripts in MBP-induced 1AE10 cells in a time-dependent manner(left panel). Image analysis of the intensity of bands is shown in theright panel. FIG. 3B and FIG. 3C: Effect of MBP on LRG localization in1AE10 cells. LRG-47 was localized in the Golgi compartment ofunstimulated 1AE10 cells (FIG. 3B, in panels B1-B3). When 1AE10 cellswere stimulated with MBP (5 μg/ml) for 4 hours, LRG-47 was redistributedfrom Golgi apparatus to the cell membrane (FIG. 3C, panels C1-C3). FIGS.3B1 & 3C1: GSK65 (marker for Golgi) staining; FIGS. 3B2 & 3C2: LRG-47staining; FIGS. 3B3 & 3C3 merge images from FIGS. 3B1/B2 and FIGS.3C1/C2, respectively. Addition of anti-LRG-47 IgG attenuates³H-thymidine incorporation (FIG. 3D) and proliferation (FIG. 3E) inMBP-treated 1AE 10 cells. FIG. 3E: CFES-labeled 1AE10 cells werestimulated by the presence of MBP (2.5 μg/ml) for the indicated times(24 to 96 hours) and stained by anti-CD44 conjugated to PE. The CFSEfluorescence profile was analyzed by FACS gated for CD44⁺ T-cells.

FIGS. 3F-3I: Blockade of LRG-47 enhances apoptosis of encephalitogenicCD4⁺ T-cells (1AE 10) in a dose- and time-dependent manner. FIG. 3F:1AE10 cells were activated with MBP (2.5 μg/ml) for 72 hours in thepresence of anti-LRG-47 IgG (0-20 μg/ml) or NI IgG (10 μg/ml). Apoptoticcells, as shown by annexin V staining, were assessed. #P<0.05, *P<0.01,n=3-5/group. Percentage of annexin V-positive cells (FIG. 3G), PI(propidium iodide)-positive cells (FIG. 3H), and live cells (FIG. 3I)were determined in the population of MBP-treated 1AE10 cells exposed toanti-LRG-47 IgG (A-19, 5 μg/ml) or NI IgG (5 μg/ml) for the indicatedtimes. *P<0.01, n=3-5/group.

FIGS. 4A-4H. Effect of blockade of LRG-47 on induction of EAE,apoptosis, and IFN-γ production. FIG. 4A: Activated 1AE10 cells wereadoptively transferred into appropriately prepared (see text) wild-type(WT) B10PL mice. Animals received anti-LRG-47 IgG (blue), nonimmune IgG(green) or vehicle (black) as indicated. Clinical symptoms were scored.*P<0.01 vs. vehicle-treated or NI IgG-treated 1AE10 cells adoptivelytransferred into WT mice. FIG. 4B: Apoptosis in the spinal cord of micesubject to adoptive transfer of activated 1AE10 cells. TUNEL-positivecells were quantified in spinal cords from WT mice after adoptivetransfer of activated 1AE10 cells alone, transfer of 1AE10 cells andtreatment with anti-LRG-47 IgG, or transfer of 1AE 10 cells andtreatment with NI IgG. * P<0.01, n=3-5 mice/group. FIG. 4C, FIG. 4C-1,FIG. 4D, FIG. 4D-1, FIG. 4E: Reduced accumulation and enhanced apoptosisof CD4 T-cells following adoptive transfer of 1AE10 cells into micetreated with anti-LRG-47 IgG. Mononuclear cells isolated from brain andspinal cord of mice subject to adoptive transfer of activated 1AE10cells 16 and 28 days earlier were stained with anti-CD4-PE and annexinV-FITC followed by FACS analysis. FACS analyses show infiltrating CD4T-cells (FIG. 4C, FIG. 4E, FIG. 4E-1) and (FIG. 4C-1) annexin V-positivecells (FIG. 4D, FIG. 4D-1) in the CNS of the latter mice. FACS datashown in panels C-D (panels 1-3) are representative of 3-5 mice/group.Panels of C4, D4 and E4 display results of 3-4 experiments. Panels ofD1-3 denote the percentage of apoptotic cells as shown by annexinV-positives in the right upper frame. FIG. 4F, FIG. 4G, FIG. 4H:Blockade of LRG-47 increases IFN-γ production. FIG. 4F: Levels of IFN-γwere determined in supernatants from cultured 1AE10 cells exposed to MBPin the presence of anti-LRG-47 IgG or NI IgG by ELISA. FIG. 4G: Cytokineproduction in CD4 T-cells from WT and LRG-47^(−/−) mice. CD4 T-cellswere isolated from spleens of WT mice and LRG-47^(−/−) mice, andcultured with MBP (2.5 μg/ml) for the indicated time. Levels of IFN-γ inculture supernatants were determined by ELISA. FIG. 4H: Levels of IFN-γin plasma from WT and LRG-47^(−/−) mice immunized with MBP to developEAE (day 14-18). * P<0.01, n=12-16 mice/group.

FIGS. 5A-5B. SiRNA inhibition of LRG-47 expression in 1AE10 Cells. FIG.5A shows the level of LRG-47 mRNA in cells measured using RT-PCT. FIG.5B shows the level of LRG-47 measured by Real-Time PCR. Afterstimulation with MBP (5 micrograms/ml) for 48 hours, 1AE10 T-cells weretransfected with siRNA targeted to mouse LRG-47.

FIG. 6. Blockade of LRG-47 expression by siRNA attenuates the clinicalsymptoms in EAE mice. MBP-activated 1AE10 cells were treated with eithersiRNA-LRG 47 or vehicle, and adoptively transferred into B10PL mice. Inwild-type (WT) B10PL mice treated with 1AE10 cells alone or 1AE10 cells,symptomatic EAE progressed rapidly, occurring in all animals in the15-20 day window, and reaching a clinical score/severity of 3-4. Incontrast, WT mice treated with 1AE10 cells exposed to siRNA-LRG 47displayed a delay in the onset of EAE and attenuation of symptomaticEAE, a clinical score of only 1-2.5. Thus, clinical symptomatologymirrors what might be expected if LRG-47 was an essential cofactor forpathogenicity of 1AE10 cells.

FIGS. 7A-7C. Expression of LRG-47 antigen in spinal cord tissue from MSpatients. FIG. 7A. LRG-47 antigen was prominently elevated inMS-affected spinal cord tissue as compared with age-matched normalcontrol by immunoblotting with specific anti-LRG-47 IgG. B-C. Byimmunostaining with specific anti-LRG 47 IgG, LRG-47 (FIG. 7B2 & FIG.7C2) was especially present in mononuclear monocytes (FIG. 7B1) and CD4+T cell (FIG. 7C1) as shown by co-stained with CD68 and CD4+,respectively. There was no positive staining when anti-LRG IgG wasreplaced by nonimmune IgG (data not shown). These data indicate thesignificance of LRG-47 in pathogenesis of MS and its relevance beyondEAE.

FIG. 8. Localization of LRG-47 antigen in spinal cords of EAE mice.Spinal cord sections were co-stained with goat anti-LRG-47 (1micrograms/ml) and rat anti-CD4 or rat anti-CD11b followed by rabbitanti-goat IgG conjugated with FITC and anti-rat-conjugated with TRITC.LRG-47 antigen (panels S2 and S5) was detected in CD4+ T-cells (S1) andCD11b-positive mononuclear cells (S4). S3 and S6 are merged with S1/S2and S3/S4, respectively. Magnification: S1-3, ×600; S4-6, ×400.

FIG. 9. Immuno-dot blotting with antibody to mouse LRG-47 of mouse serumfrom MBP-induced EAE mice at day 7 and 12 and naïve mice demonstrated anincrease in LRG-47 in serum of EAE mice compared to serum from naïvemice. Levels of LRG-47 were quantified by NIH image program.

FIGS. 10A-10B. Immuno-dot blotting with antibody to human LRG-47 ofcerebral spinal fluid (CSF) (FIG. 10A) and serum (FIG. 10B) from MSpatients demonstrated an increase in LRG-47 in MS patients compared toage-matched control patients. Levels of LRG-47 were quantified by NIHimage program.

DETAILED DESCRIPTION

We have discovered that LRG-47 (also called p47 GTPase), plays a centralrole in the pathogenesis of multiple sclerosis, and that inhibition ofLRG-47 activity by anti-LRG-47 antibodies or of LRG-47 expression bysiRNA dramatically reduce the pathology and symptoms of multiplesclerosis. Therefore certain embodiments of the invention are directedto the therapeutic use of anti-LRG-47 antibodies (mouse or rabbit orother antibodies that are humanized or human antibodies to LRG-47,preferably antibodies made against human LRG-47) or siRNA or antisensenucleotides that specifically hybridize with the gene or mRNA or cDNAencoding human LRG-47 to treat or prevent multiple sclerosis and otherautoimmune diseases that are T-cell-mediated. Other embodiments aredirected to methods for the diagnosis of multiple sclerosis or todetermining the aggressiveness of multiple sclerosis by determining theamount of human LRG-47 or LRG-47 mRNA in a biological sample from thepatient. Other embodiments are directed to transgenic LRG-47−/− mice.Certain embodiments are directed to various humanized anti-LRG-47antibodies and to their diagnostic and therapeutic use.

We have discovered that LRG-47 which is known for its essentialcontribution to host resistance to certain intracellular pathogens,plays a central role in the pathogenesis of Experimental AutoimmuneEncephalitis (EAE) that is a model for Multiple Sclerosis in animals.The experiments herein show that LRG-47 increases the survival ofautoreactive T-cells, the levels of which are known to be increased inanimals having EAE. We show that expression of LRG-47 occurs early inthe course of myelin basic protein (MBP)-induced EAE in the centralnervous system (CNS), especially in cells of lymphoid and mononuclearphagocytic origin. Using classical genetics we discovered thathomozygous LRG-47 null mice (hereafter “LRG-47 null mice”) wereresistant to MBP-induced EAE, and CD4 T-cells in the spleen and CNS ofthese animals displayed decreased proliferative capacity and underwentincreased apoptosis. LRG-47 null mice also displayed dysregulation ofinterferon-γ. Certain embodiments of the invention are directed toLRG-47−/− transgenic mice.

The results of experiments presented below further show that anencephalitogenic CD4 Th1 clone (1AE10 cells) showed rapid upregulationof LRG-47 after exposure to MBP in vitro, while blockade of LRG-47expression in the presence of MBP suppressed proliferation and inducedcell death. Adoptive transfer of 1AE10 cells treated with anti-LRG IgGinto naïve WT mice attenuated EAE when the mice were treated with MBP.These data indicate that one way in which the blockade of LRG-47alleviates EAE is by suppressing expansion of activated CD4 T-cells.Importantly, we also discovered that LRG-47 expression levels aredramatically increased in spinal cord tissues taken from a patientdiagnosed with Multiple Sclerosis (MS). The fluorescence detected byimmunoblotting spinal cord tissue from an MS patient using an isolatedantibody against LRG-47 was 16 times more intense than in normalanimals. Further, we were able to block LRG-47 expression using smallinterfering RNA in 1AE10 cells in the EAE model and thereby reduce theseverity of the disease and delay its onset.

These discoveries enable a therapy for treating or preventing MS byreducing the level of LRG-47 expression in an animal preferably a humanthat has the disease or is at risk of developing MS; preferably byreducing the level of expression in the central nervous system, moreparticularly in the spinal cord. Such inhibition can be accomplished byadministering siRNA to an animal in an amount that either reduces LRG-47expression in a biological sample taken from the animal, or in an amountthat reduces the symptoms of MS in the animal. Since increased levels ofactivated CD4 T-cells are implicated in the pathogenesis of autoimmunedisorders in general, certain embodiments of the invention are directedto methods of treating or preventing an autoimmune disorder in an animalpreferably a human having elevated levels of activated CD4 T-cells byadministering a therapeutic agent that reduces human LRG-47 expression.

Interferon-gamma (IFN-γ) plays a central role in host resistance toinfection and regulation of the immune system. Thus, it is notsurprising that INF-γ is an essential factor in CD4 T-cell homeostasisduring the immune response, including activation-induced cell death[1-3]. In the setting of Experimental Autoimmune Encephalitis (EAE),INF-γ-deficient mice display a progressive and fatal clinical courseassociated with increased proliferation and decreased apoptosis ofactivated CD4 T-cells in response to antigen [3]. This pattern is alsoseen in other models of autoimmune diseases. These observationsindicated to us the likelihood that downstream effectors of IFN-γ wouldalso have important roles in immunobiology. Specifically, anIFN-γ-inducible family of intracellular 47 kDa GTPases has been shown tocontribute to resistance to intracellular pathogens [4-9]. One member ofthis family, LRG-47, is essential in resistance to Mycobacterialtuberculosis and Toxoplasma gondii, whereas other members are involvedin the response to different pathogens [4-9]. The results belowdemonstrate a role for LRG-47 in survival of autoreactive CD4 T-cells.In vivo and in vitro evidence shows that LRG-47 deficient mice showsuppressed EAE because they do not show expansion of activated CD4T-cells and decreased apoptosis of activated T cells.

We have recently demonstrated that receptor for advanced glycationendproducts (RAGE), a multiligand member of the immunoglobulinsuperfamily, can mediate induction of EAE under certain conditions. Inthe myelin basic protein (MBP) model used in the experiments describedblow, blockade of RAGE prevents induction of symptomatic EAE, at leastin part by inhibiting migration of immunocytes into the central nervoussystem [10]. In order to probe the underlying mechanisms, we performedmicroarray analysis to identify differences in gene expression betweenmice-induced by MBP and naïve mice. We discovered that LRG-47 wassignificantly upregulated in EAE-induced animals treated with MBPcompared to naïve mice. The studies below that LRG-47 plays a key rolein the pathogenesis of EAE and other autoimmune diseases associated withincreased levels of activated T cells.

Results Expression of LRG-47 in Mouse EAE

PCR demonstrated ≈30-fold upregulation of LRG-47 mRNA in spinal cordtissue in mice 14 days after treatment with MBP, when symptomatology wasapproaching a peak (15-17 days; see below), compared with controls(untreated animals or those receiving only complete QuantitativeFreund's adjuvant, CFA; p<0.001)(FIG. 1A). Northern analysis on spinalcord from animals subjected to MBP-induced EAE was performed at severaltime points. A trend towards higher levels of LRG-47 transcripts wasfirst noted on day 10 (post-MBP treatment), and a statisticallysignificant increase was seen by day 14 (FIG. 1B-C). These data indicatea close correspondence between LRG-47 expression and symptomatic EAE.LRG-47 antigen was detected in CD4 T-cells (FIG. 8, in panels S1-S3) andmononuclear phagocytes (FIG. 8, in panels S4-S6) in spinal cords fromEAE-induced mice by confocal microscopy. LRG-47 antigen was colocalizedin a subpopulation of cells also staining for CD4 (FIG. 8, in panel S3)and CD11b (FIG. 8, in panel S6). These observations are consistent witha potential role of p47 GTPases in cells critical to the evolving hostresponse.

Deficiency of LRG-47 Protects Animal from EAE

The close association of EAE with LRG-47 mRNA/protein expression led usto explore whether this mediator had a pathogenic role in EAE. To dothis we used homozygous mutant mice devoid of LRG-47 (LRG-47^(−/−)) inthe B10PL strain. For these studies, we employed the MPB model in whichLRG-47^(−/−) or age/strain-matched B10PL littermate mice were immunizedwith an acylated N-terminal peptide fragment comprised of nine residuesfrom myelin basic protein (1-9NAc MBP)[10]. Compared to B10PL controls,LRG-47^(−/−) mice exhibited strikingly reduced incidence and severity ofdisease (FIG. 1D, Table 1). Hemizygous LRG-47^(+/−) mice showed a slightreduction in the severity of symptomatic disease compared withstrain-matched wild-type (WT) littermates, though there was nosignificance between WT controls and LRG-47^(+/−) mice (FIG. 1D).Histologic analysis of spinal cord tissue harvested at the time of peaksymptoms (day 18) after treatment with MBP demonstrated a strikingreduction in the inflammatory cell infiltrates in LRG-47^(−/−) mice,compared with other genotypes (FIG. 1E). Thus, pathologic eventscorrelate closely with symptomatology in terms of protection fromdisease in LRG-47^(−/−) mice immunized with MBP.

TABLE 1 The percentage of each group of mice developing disease.Genotype N Incidence % LRG+/+ 12/12 100 LRG+/− 12/12 100 LRG−/−  2/1216.7

To begin to analyze mechanisms through which LRG-47 contributes to thepathogenesis of EAE, we analyzed the CD4 T-cell population inLRG-47^(−/−) and control mice. The percentage of CD4 T-cells in thecentral nervous system (CNS), including brain and spinal cord eluates,from LRG-47^(−/−) mice 20 days after MBP treatment was reduced ˜50%,compared with strain-matched controls (22.7% and 46.6% for LRG-47^(−/−)and controls, respectively)(FIG. 2A). The latter reduction wasespecially evident in the activated CD4 T-cell population that expresseshigh levels of CD44 (CD44^(hi)). Activated CD4 T-cells comprised only8-9% of cells in spinal cord eluates from EAE-induced LRG-47^(−/−) miceversus 32% in EAE-induced WT animals (FIG. 2A). Most striking was the≈3-fold increase in apoptotic cells, based on annexin V staining, in theCD4 T-cell population harvested on day 20 from the CNS of LRG-47^(−/−)mice compared with controls (30% versus 9%, for LRP-47^(−/−) andcontrols, respectively; FIG. 2A). Similarly, the percentage of CD44^(hi)activated CD4 T-cells was significantly reduced in the lymphocytepopulation from lymph nodes of LRG-47^(−/−) mice compared to non-Tg(transgenic) littermate controls (FIG. 2B). A non-Tg littermate is anage-matched normal mouse in the same litters expressing endogenouslevels of LRG-47 without transgene manipulation. Apoptosis of CD4 Tcells, which includes activated T cells (shown as TUNEL-positive cells)was increased in the lymph nodes from LRG-47^(−/−) mice, compared withWT littermates (FIG. 2C). To better understand the relationship betweenLRG-47 expression and cell proliferation in CD4 cells in vivo, micereceived intraperitoneal BrdU, and FACS analysis was performed on cellsisolated from the CNS using anti-CD4 and anti-BrdU IgG. Compared with WTlittermate controls, cellular eluates from the CNS of LRG-47^(−/−) micedisplayed a strong reduction in the percentage of CD4 T-cellsincorporating BrdU (4.69% in LRG-47^(−/−) vs. 33% in WT mice; FIG. 2D).These data show a central role for LRG-47 in activation and/or expansionof autoreactive T-cells in EAE. Without being bound by theory,potentially, LRG-47 might promote survival of autoreactive T-cells inEAE.

These in vivo observations concerning a possible relationship betweenLRG-47 expression and the proliferative potential of CD4 T-cells led usto perform in vitro experiments to directly address this issue. T-cellswere purified from spleens and lymph nodes of mice immunized 7 dayspreviously with MBP, and cultured in the presence of MBP. T-cells fromLRG-47^(−/−) mice showed diminished proliferation in response to MBP,compared with T-cells from WT littermate controls (FIG. 2E).Correspondingly, the percentage of annexin V-positive cells wasincreased in LRG-47^(−/−) mice indicating increased apoptosis, versus WT(wild type) littermate controls (FIG. 2F). Further analysis of CD4T-cells isolated from spleens of EAE mice after MBP treatment displayedan increase in the percentage of TUNEL-positive CD4 T-cells fromLRG-47^(−/−) mice compared with WT mice (FIG. 2G). These experimentsprovide further support the role of LRG-47 in activation of autoreactiveT cells, and decreased apoptosis of autoreactive T cells during EAE.

Induction of EAE by Encephalitogenic T Cells: Effect of LRG-47

We next focused our experiments on an encephalitogenic CD4 Th1 T-cellclone (1AE10)[10] in order to assess the contribution of LRG-47 to EAEpathogenicity. Two approaches were utilized in these studies; 1)evaluation of the effect of LRG-47 on activation, proliferation andapoptosis of 1AE10 cells in vitro; and 2) determination of the impact ofblocking LRG-47 activity on induction of EAE following adoptive transferof activated 1AE10 cells in vivo. In order to characterize LRG-47expression in 1AE10 cells, cultures were activated by addition of 1-9NAcMBP. LRG-47 transcripts increased by ˜6-8-fold comparing day 0 to days4-10 after stimulation with MBP (FIG. 3A). High levels of LRG-47transcripts were maintained from days 4-10, and thereafter decreased. Inview of heightened expression of LRG-47 in activated 1AE10 cells, weassessed whether inhibition of LRG-47 would modulate properties of 1AE10cells.

LRG-47 mainly localizes to the Golgi apparatus [11, 12] as shown bycolocalization with Golgi marker GRAS65. Unstimuated 1AE10 cells werestained with antibodies to LRG-47 (FIG. 3B2) or to GRAS65 (FIG. 3B1).LRG-47 was detected in Golgi apparatus (FIG. 3B3). However, afterstimulation of 1AE10 cells with MBP (5 μg/ml) for 4 hours, LRG-47translocated from Golgi to the plasma membrane of cell surface (FIG.3C2-3) as shown on non-permeable cells. Therefore, LRG-47 appears toredistribute to the cell surface during activation of 1AE10 cellsinduced by MBP. These data led us to determine the effect of inhibitingLRG-47 on properties of 1AE10 cells using specific antibodies to LRG-47.The location of LRG-47 on the cell surface of the activated cells makesit accessible to antibodies for therapeutic intervention to reduce itseffect.

Activation of 1AE10 cells for 4 days in culture with MBP resulted in acorresponding increase in ³H-thymidine incorporation which was blockedin a dose-dependent manner by anti-LRG-47 IgG (A19), but not bynonimmune (NI) IgG (FIG. 3D). Consistent with these data, FACS analysisof CFSE-FITC-labeled 1AE10 cells activated by exposure to MBP displayedtime-dependent proliferation; cell labeling increased from 0.37% to30.6% corresponding to the interval from 24 hour to 96 hours. The latterproliferative response was inhibited by ≈10-fold at the 96 hour timepoint on addition of anti-LRG-47 IgG (A19). In contrast, NI IgG had noeffect (FIG. 3E). These data indicate that blockade of LRG-47 suppressesantigen induced proliferation of encephalitogenic T-cells.

Apoptosis of lymphocytes is one of the major homeostatic mechanisms inthe immune system. In view of the enhanced susceptibility ofLRG-47^(−/−) mice to protozoan and mycobacterial infection [7, 13, 14],we sought to determine whether LRG-47 functioned as a survival factor inMBP-primed encephalitogenic T-cells. To address this issue, we examinedif the lack of proliferative activity in 1AE10 cells activated in thepresence of MBP actually reflected an enhanced degree of apoptosis.MBP-treated 1AE10 cells displayed a dose-dependent increase in thepopulation of annexin V-positive cells as the concentration ofanti-LRG-47 IgG was increased from 5 to 20 μg/ml reaching up to ≈70% ofthe cells, whereas NI IgG was without effect (72 hr time point; FIG.3F). These results were paralleled by those observed on time-dependentassessment of annexin V staining (FIG. 3G), propidium iodide uptake(FIG. 3H), and live cell assay (FIG. 3I) in 1AE10 cells. Addition ofanti-LRG-47 IgG showed evidence of increased cell death/apoptosis ineach case. These data show that LRG-47 is a key factor in expansion ofencephalitogenic CD4 T-cells in response to antigen, in this case MBP,by inhibiting apoptosis.

The ultimate confirmation of this result concerns the encephalitogenicpotential of 1AE10 cells in vivo. MBP-activated 1AE10 cells were treatedwith either anti-LRG-47 IgG or NI IgG, and adoptively transferred intoB10PL mice. Wild-type (WT) B10PL mice treated with 1AE10 cells alone orwith 1AE10 cells/NI IgG, showed symptomatic EAE that progressed rapidly,occurring in all animals in the 12-14 day window, and reaching aclinical score/severity of 3-4 (FIG. 4A, Table 2). In contrast, WT micetreated with 1AE10 cells exposed to anti-LRG-47 IgG (A-19) displayedonly 77.8% incidence of symptomatic EAE, with a quite different course(delayed) and a dramatically lower clinical score of only 1-1.5. Thus,clinical symptomatology mirrors what is expected if LRG-47 was anessential cofactor for pathogenicity of 1AE10 cells.

TABLE 2 Transfer EAE N Incidence % WT. 9/9 100 Wt./A19 7/9 77.8Wt./NI-IgG 6/6 100

Our clinical findings in mice indicated the importance of analyzing thenature of cells infiltrating the spinal cord under each of thesesituations following induction of EAE by infusion of 1AE10 cells. At day14-16, during the peak of EAE symptoms, there were no significantdifferences in the number of CD4 T-cells in spinal cord eluates among WTmice adoptively transferred with 1AE10 cells that were treated withanti-LRG-47 IgG, control NI IgG, or in 1AE10 cells alone without anytreatment. (FIG. 4C, FIG. 4C-1). However, apoptotic cells in spinal cordeluates, as shown by annexin V and TUNEL staining, showed substantialdifferences in each of these situations. Whereas there were fewerapoptotic cells in eluates from WT mice transferred with 1AE10 cellsalone or treated with control NI IgG, there were significantly moreapoptotic cells in samples from WT mice transferred with 1AE10 cellstreated with anti-LRG-47 IgG (A19) (FIG. 4B, FIG. 4D, FIG. 4D-1). Thus,death of CD4 T-cells in the spinal cord between days 14 and 28, was thelikely explanation for their reduction in spinal cord eluates in WT micetransferred with 1AE10 cells treated with anti-LRG-47 IgG, versus WTmice treated with 1AE10 cells alone observed at day 28 (FIG. 4E, FIG.4E-1).

Effect of LRG-47 on IFN-γ Induction

To further understand the role of LRG-47 in regulating CD4 T-cellfunction/survival in the setting of pathogenic auto-immunity, weexamined how LRG-47 expression affects the expression of IFN-γ in 1AE10cells. Cultured 1AE10 cells were stimulated with MBP-derived peptidealone or with MBP-derived peptide in the presence of either anti-LRG-47IgG or NI IgG. IFN-γ was measured in supernatants (FIG. 4F). We foundthat LRG-47 is a negative regulator of IFN-γ. Inhibition of LRG-47 incultured 1AE10 cells with anti-LRG-47 IgG resulted in dose- andtime-dependent increases in levels of IFN-γ (FIG. 4F) secreted into themedium. Moreover, IFN-γ levels were increased in cultured CD4 T-cellsisolated from lymph nodes/spleens of LRG-47^(−/−) mice at 7 days afterimmunization with MBP-derived peptide (FIG. 4G). In addition, levels ofIFN-γ were elevated in the sera of LRG-47^(−/−) mice compared to WT miceinduced with MBP to develop EAE (FIG. 4H).

Multiple sclerosis is the most common autoimmune disease of the centralnerve system (CNS). T lymphocytes that are reactive with components ofmyelin sheaths are thought to play key roles in disease pathogenesis.Experimental autoimmune encephalitis (EAE) is the best animal model ofmultiple sclerosis. During EAE, the interaction of active CD4+ T cellsand myelin antigens apparently provoke a massive destructiveinflammatory response that promotes continuing proliferation of T cellsand macrophage activation that escalates to intensive inflammation anddemyelination of nerves in the CNS. The presence of LRG-47 inauto-reactive CD4+ T cells and macrophages, and increased expression ofLRG-47 in EAE-affected spinal cord tissue indicate a key role of LRG-47on the induction of EAE. Blockade of LRG-47 expression promotesapoptosis, which diminishes expansion of activation and proliferation ofMBP-reactive CD4+ T cells. Furthermore, activation of anencephalitogenic CD4+ Th1 T-cell clone with MBP was clearly suppressedin the presence of anti-LRG-47 specific IgG but not by non-immune IgG.At the same time, apoptotic cells were significantly increased inresponse to LRG-47 blockade. Also, LRG-47 blockade prevented inductionof EAE when fully activated 1AE10 cells were transferred into B10.PLmice. Blockade of LRG-47 also increased apoptotic encephalitogenic CD4+T cells in EAE-affected spinal cord tissues. These data show arequirement of LRG-47 protein for persistence of CD4 T-cells in the CNSto propagate the immune/inflammatory response. Thus it is likely thatdeath of encephalitogenic CD4 T-cells and their decreased proliferationaccount for the relatively mild course of EAE in WT animals adoptivelytransferred with 1AE10 cells treated with anti-LRG-47.

IFN-γ has been shown to function as a negative regulator of lymphocyteexpansion, eliminating activated CD4 T-cells by promoting apoptosisduring the immune response [1-3, 17]. Without being bound by theory, wepropose that blockade of LRG-47 interrupts a negative feedback loop thatis triggered after the immune response is initiated, thereby limitingsubsequent expression of IFN-γ. As a result, re-expression of IFN-γleads to levels which attenuate the ongoing immune response.

While LRG-47 has been shown to contribute to the host response tointracellular bacterial infection [9, 12, 16] and has been suggested tofunction as a survival factor in the context of mycobacterial infection[14, 18]. Our data indicate that it is also present in CD4 T-cells whereit promotes survival of pathogenic self-reactive T-cells at least inpart by preventing T-cell apoptosis. Without being bound by theory, wepropose that induction of EAE by activation of autoreactive MBP-specificT-cells leads to early (day 7) secretion of IFN-γ initiating a DTH(Delayed Type Hypersensitivity) response in the CNS. Induction of LRG-47by IFN-γ facilitates the survival of the expanded self-reactive T-cellpopulation, thus LRG-47 also plays an important role in the pathogenesisof autoimmune disease including MS and EAE. This protective role ofLRG-47 for encephalitogenic CD4 T-cells in EAE (thereby enhancing theirpathogenicity) contrasts with its role in buttressing a protective hostresponse to certain pathogens [4, 7, 12, 14]. The translocation ofLRG-47 to the outer cell membrane adds a new and unexpected dimension tothe biology of this GTPase. Its location on the outer cell membranemeans that it is an accessible target for immune therapy (i.e. blockingLRG-47 activity with anti-LRG-47 antibodies.) Certain embodiments of theinvention are directed to treating or preventing an autoimmune diseaseincluding MS by administering anti-LRG47 antibodies or fragments orvariants thereof, preferably in humanized form and preferably againsthuman LRG-47, in order to reduce LRG-47 expression.

SiRNA Effectively Blocks LRG-47 Expression in 1AE10 T-Cells

To test the ability of SiRNA to block LRG-47 expression, 1AE10 T-cellswere stimulated with MBP (5 micrograms per ml) for 48 hours. 1AE10 Tcells were transfected with siRNA targeted to mouse LRG-47 (sensesequence: 5′-GGUUACCUGAGGUCAGUAGtt-3′ SEQ ID NO: 5, antisense sequence:5′-CUACUGACCUCAGGUAACCtg-3′ SEQ ID NO: 6,) using siPORT Amine (Ambion)for additional 24. Levels of LRG-47 mRNA in cells were determined byreal-time quantitative PCR and RT-PCR. The level of LRG-47 mRNA wasmeasured using real-time quantitative PCR (right) and RT-PCR (left). Theresults shown in FIG. 5 show that LRG-47 expression was reduced by about40% by transfection with the siRNA. In addition to reviewing the levelof LRG-47 mRNA expression, we also looked at the clinical symptoms inEAE in vivo. Blockade of LRG-47 expression by siRNA attenuates theclinical symptoms in EAE mice. MBP-activated 1AE10 cells were treatedwith either siRNA-LRG 47 or vehicle, and adoptively transferred intoB10PL mice. In wild-type (WT) B10PL mice treated with 1AE10 cells aloneor 1AE10 cells, symptomatic EAE progressed rapidly, occurring in allanimals in the 15-20 day window, and reaching a clinical score/severityof 3-4. In contrast, WT mice treated with 1AE10 cells exposed tosiRNA-LRG 47 displayed a delay in the onset of EAE and attenuation ofsymptomatic EAE, a clinical score of only 1-2.5. Thus, clinicalsymptomatology mirrors what might be expected if LRG-47 was an essentialcofactor for pathogenicity of 1AE10 cells.

As is discussed below certain embodiments of the invention are directedto methods for treating or preventing MS by administering an agent thatreduces LRG-47 expression, preferably human LRG-47 for human use,including siRNAs. Although we tested only one siRNA against a murineLRG-47, the field of antisense technology is well established and it isroutine in the art to develop antisense or siRNA molecules that inhibitexpression of a given target gene or mRNA.

LRG-47 Levels are Elevated about Spinal Cord, CSF and Serum from MSPatients

In order to determine whether LRG-47 levels are elevated in a humanpatient having MS, we analyzed MS-affected spinal cord tissues. LRG-47levels were measured using quantitative real-time PCR, which showed anapproximately 16-fold increase in LRG-47 in the MS-affected patientsample, compared to a spinal cord sample from an age-matched unafflictedcontrol. FIG. 7 shows expression of LRG-47 antigen in spinal cord tissuefrom MS patients. FIG. 7A: LRG-47 antigen was prominently elevated inMS-affected spinal cord tissue as compared with age-matched normalcontrol by immunoblotting with specific anti-LRG-47 IgG. FIG. 7B-C:Immunostaining with specific anti-LRG 47 IgG, showed that LRG-47 (FIG.7C, panels B2 & C2) was especially intense in mononuclear monocytes(FIG. 7B, panel B1) and CD4+ T cell (FIG. 7B, panel C1), as shown byco-staining with CD68 and CD4+, respectively. There was no positivestaining when anti-LRG IgG was replaced by nonimmune IgG (data notshown). These results taken together show the significance of LRG-47expression in the pathogenesis of MS and its relevance to autoimmunediseases other than EAE.

FIG. 8 shows the localization of LRG-47 antigen in spinal cords of EAEmice. Spinal cord sections were co-stained with goat anti-LRG-47 (1micrograms/ml) and rat anti-CD4 or rat anti-CD11b, followed by rabbitanti-goat IgG conjugated with FITC, and anti-rat-conjugated with TRITC.LRG-47 antigen (FIG. 8, panels S2 and S5) was detected in CD4+ T-cells(FIG. 8, panel S1) and CD11b-positive mononuclear cells (FIG. 8, panelsS4). Panels S3 and S6 are merged with S1/S2 and S3/S4, respectively.Magnification: S1-3, ×600; S4-6, ×400.

Recently, we showed that level of LRG-47 was increased in the serum ofEAE mice compared to the serum of naïve mice. Similarly, LRG-47 wasup-regulated in the cerebral spinal fluid (CSF) or serum taken from MSpatients at the activated stage. FIG. 9 shows immuno-dot blotting withantibody to mouse LRG-47 of mouse serum demonstrating a significantincrease in LRG-47 in the serum of EAE mice compared to serum from naïvemice. Levels of LRG-47 were quantified by NIH image program. Naïve miceshowed about 25 units of intensity compared to about 85 for EAE mice atday 7 and about 80 for day 12, indicating more than a 3-fold increase inserum LRG-47. We next looked at human CSF and serum from MS patientscompared to age-matched control patients using the anti-human-LRG-47 ABantibody that was made in our laboratory. The result was an approximate4-fold increase in the levels of LRG-47 in the serum and CSF of MSpatients. Based on these results we describe diagnostic methods belowbased on measuring elevated levels of secreted LRG-47 in serum or CSF ofa patient compared to controls. Certain embodiments are also directed tothe new anti-human-LRG-47 138AB antibody itself, or fragments orvariants thereof, preferably in humanized form. Embodiments are alsodirected to pharmaceutical formulations comprising the newanti-human-LRG-47 138AB antibody itself, or fragments or variantsthereof, preferably in humanized form; and to its use to treat, preventor diagnose MS or other autoimmune disease.

We made rabbit anti human LRG-47 antibody, called 138AB as follows:Synthetic peptides [Ac-VGHEGKASPPTELVKATQR-amide (54-71) SEQ ID NO: 7and Ac-EDMGKKFYIVWTKLDMDLC-amide (132-149)] SEQ ID NO: 8 were immunizedto rabbit, and then antiserum was affinity purified to IgG. Thisaffinity purified antibody specific for human LRG was used for ourstudy. Certain embodiments are directed to this antibody or a fragmentor variant thereof preferably in humanized form, and to its therapeuticuse to treat, prevent or diagnose MS or other autoimmune disease.

Treatment and Prevention of MS Using Anti-LRG-47 Antibodies

Certain embodiments of the invention are directed to methods to treat orprevent MS in an animal, preferably a human, by administering atherapeutically effective amount of an isolated anti-LRG-47 antibody orbiologically active fragment thereof, including polyclonal andmonoclonal antibodies preferably humanized. In a preferred embodimentthe isolated antibody is a polyclonal anti-human LRG47 antibody named138AB or fragment or variant thereof that was made in our laboratory asdescribed herein. An embodiment of the invention is also directed tothis isolated polyclonal anti-human LRG47 138AB or fragment or variantthereof, preferably a humanized form, and to its therapeutic use asdescribed herein. In another preferred embodiment the isolated antibodyfor use in treating or preventing MS includes humanized forms of thepolyclonal anti-LRG47 antibodies commercially available from Santa CruzBiotechnology, Inc. including those listed below, or a fragment orvariant thereof. These antibodies can also be used to measure the levelof secreted LRG-47 in a biological sample as described herein fordiagnostic testing, and can be included in the kits described below. Nonhumanized forms can be used for the diagnostic claims herein.

For the purpose of this invention, a therapeutically effective amount ofa compound is an amount that achieves the desired biologic ortherapeutic effect, namely an amount that prevents, reduces orameliorates one or more symptoms of the enumerated diseases beingtreated or prevented. In some embodiments the starting point fordetermining a therapeutic amount is an amount that significantly reducesthe amount of secreted LRG-47 protein or LRG-47 mRNA in a patientbiological sample, (i.e. a statistically significant reduction,preferably a two fold reduction).

PRODUCT CATALOG ISO- APPLI- NAME # TYPE EPITOPE CATIONS LRG-47 (M-95)sc-33216 rabbit 315-409 WB, IP, Antibody IgG (m) IF, ELISA LRG-47 (P-20)sc-11074 goat N-terminus WB, IF, Antibody IgG (m) ELISA LRG-47 (M-16)sc-11077 goat C-terminus WB, IF, Antibody IgG (m) ELISA LRG-47 (A-19)sc-11075 goat N-terminus WB, IF, Antibody IgG (m) ELISA

LRG-47 specific siRNA gene silencers are also available. These include:LRG-47 siRNA (m): sc-41794.

The location of LRG-47 protein on the surface of activated T cells isparticularly important for treating or preventing MS using antibodytherapy because this target protein is accessible to the antibodies.Anti-LRG-47 therapy targets circulating activated T cells, so theantibody does not need to cross the BBB. The amount of anti-LRG-47 to beadministered therapeutically ranges from about 1 ug to 100 ug/ml. Thisamount typically varies and can be an amount sufficient to achieve serumtherapeutic agent levels typically of between about 1 microgram permilliliter and about 10 micrograms per milliliter in the subject. In thecontext of the present invention, anti-LRG-47 antibodies are a type ofneutralizing antibody that prevents LRG-47 from activating T cells.

An “antibody” refers to an intact immunoglobulin or to anantigen-binding portion thereof that competes with the intact antibodyfor specific binding. Antigen-binding portions may be produced byrecombinant DNA techniques or by enzymatic or chemical cleavage ofintact antibodies. Antigen-binding portions include, inter alia, Fab,Fab′, F(ab′).sub.2, Fv, dAb, and complementarity determining region(CDR) fragments, single-chain antibodies (scFv), chimeric antibodies,diabodies and polypeptides that contain at least a portion of animmunoglobulin that is sufficient to confer specific antigen binding tothe polypeptide.

An “immunoglobulin” is a tetrameric molecule. In a naturally-occurringimmunoglobulin, each tetramer is composed of two identical pairs ofpolypeptide chains, each pair having one “light” (about 25 kDa) and one“heavy” chain (about 50 70 kDa). The amino-terminal portion of eachchain includes a variable region of about 100 to 110 or more amino acidsprimarily responsible for antigen recognition. The carboxy-terminalportion of each chain defines a constant region primarily responsiblefor effector function. Human light chains are classified as .kappa. and.lamda. light chains. Heavy chains are classified as .mu., .DELTA.,.gamma., .alpha., or .epsilon., and define the antibody's isotype asIgM, IgD, IgG, IgA, and IgE, respectively. Within light and heavychains, the variable and constant regions are joined by a “J” region ofabout 12 or more amino acids, with the heavy chain also including a “D”region of about 10 more amino acids. See generally, FundamentalImmunology Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989))(incorporated by reference in its entirety for all purposes). Thevariable regions of each light/heavy chain pair form the antibodybinding site such that an intact immunoglobulin has two binding sites.

Immunoglobulin chains exhibit the same general structure of relativelyconserved framework regions (FR) joined by three hypervariable regions,also called complementarity determining regions or CDRs. The CDRs fromthe two chains of each pair are aligned by the framework regions,enabling binding to a specific epitope. From N-terminus to C-terminus,both light and heavy chains comprise the domains FR1, CDR1, FR2, CDR2,FR3, CDR3 and FR4. The assignment of amino acids to each domain is inaccordance with the definitions of Kabat Sequences of Proteins ofImmunological Interest (National Institutes of Health, Bethesda, Md.(1987 and 1991)), or Chothia & Lesk J. Mol. Biol. 196:901 917 (1987);Chothia et al. Nature 342:878 883 (1989).

An Fab fragment is a monovalent fragment consisting of the VL, VH, CLand CH I domains; a F(ab′).sub.2 fragment is a bivalent fragmentcomprising two Fab fragments linked by a disulfide bridge at the hingeregion; a Fd fragment consists of the VH and CH1 domains; an Fv fragmentconsists of the VL and VH domains of a single arm of an antibody; and adAb fragment (Ward et al., Nature 341:544 546, 1989) consists of a VHdomain.

A single-chain antibody (scFv) is an antibody in which a VL and VHregions are paired to form a monovalent molecules via a synthetic linkerthat enables them to be made as a single protein chain (Bird et al.,Science 242:423 426, 1988 and Huston et al., Proc. Natl. Acad. Sci. USA85:5879 5883, 1988). Diabodies are bivalent, bispecific antibodies inwhich VH and VL domains are expressed on a single polypeptide chain, butusing a linker that is too short to allow for pairing between the twodomains on the same chain, thereby forcing the domains to pair withcomplementary domains of another chain and creating two antigen bindingsites (see e.g., Holliger, P., et al., Proc. Natl. Acad. Sci. USA90:6444 6448, 1993, and Poljak, R. J., et al., Structure 2:1121 1123,1994). One or more CDRs may be incorporated into a molecule eithercovalently or noncovalently to make it an immunoadhesin. Animmunoadhesin may incorporate the CDR(s) as part of a larger polypeptidechain, may covalently link the CDR(s) to another polypeptide chain, ormay incorporate the CDR(s) noncovalently. The CDRs permit theimmunoadhesin to specifically bind to a particular antigen of interest.

An antibody may have one or more binding sites. If there is more thanone binding site, the binding sites may be identical to one another ormay be different. For instance, a naturally-occurring immunoglobulin hastwo identical binding sites, a single-chain antibody or Fab fragment hasone binding site, while a “bispecific” or “bifunctional” antibody hastwo different binding sites.

An “isolated antibody” is an antibody that (1) is not associated withnaturally-associated components, including other naturally-associatedantibodies, that accompany it in its native state, (2) is free of otherproteins from the same species, (3) is expressed by a cell from adifferent species, or (4) does not occur in nature.

The term “human antibody” includes all antibodies that have one or morevariable and constant regions derived from human immunoglobulinsequences. In a preferred embodiment, all of the variable and constantdomains are derived from human immunoglobulin sequences (a fully humanantibody). These antibodies may be prepared in a variety of ways, asdescribed below.

A humanized antibody is an antibody that is derived from a non-humanspecies, in which certain amino acids in the framework and constantdomains of the heavy and light chains have been mutated so as to avoidor abrogate an immune response in humans. Alternatively, a humanizedantibody may be produced by fusing the constant domains from a humanantibody to the variable domains of a non-human species. Examples of howto make humanized antibodies may be found in U.S. Pat. Nos. 6,054,297,5,886,152 and 5,877,293, incorporated herein by reference.

The term “chimeric antibody” refers to an antibody that contains one ormore regions from one antibody and one or more regions from one or moreother antibodies.

Fragments or analogs of antibodies can be readily prepared by those ofordinary skill in the art following the teachings of this specification.Preferred amino- and carboxy-termini of fragments or analogs occur nearboundaries of functional domains. Structural and functional domains canbe identified by comparison of the nucleotide and/or amino acid sequencedata to public or proprietary sequence databases. Preferably,computerized comparison methods are used to identify sequence motifs orpredicted protein conformation domains that occur in other proteins ofknown structure and/or function. Methods to identify protein sequencesthat fold into a known three-dimensional structure are known. Bowie etal. Science 253:164 (1991).

Antisense Nucleotides and siRNA

Certain embodiments of the invention are directed to the use ofantisense or siRNA to block expression of LRG-47 thereby treating orpreventing MS or other autoimmune or T-cell mediated diseases,preferably in humans. Antisense nucleotides can be designed usingroutine skill in the art to target human DNA or mRNA encoding LRG-47 asis described in more detail below. The full cDNA sequence for the humanLRG-47 gene is not yet known; the partial sequence known at the presenttime is public and is set forth in BC128168, incorporated herein byreference as SEQ ID NO: 1. When the full sequence becomes known andpublished, persons of skill in the art will be able to constructappropriate antisense nucleotides and siRNA using methods known in theart. The gene and mRNA sequence for mouse LRG-47 is public, isidentified by accession NO: U19119, and is incorporated herein byreference as SEQ ID. No:3 (gene sequence) and SEQ ID NO: 4 (amino acidsequence).

Another embodiment for treating or preventing multiple sclerosis in ananimal preferably a human, has the steps:

a. determining a pre-treatment level of human LRG-47 protein in apre-treatment biological sample taken from the animal,

b. administering an amount of an antisense nucleotide or siRNA thatspecifically hybridizes with the gene or mRNA encoding LRG-47,

c. determining a post-treatment level of LRG-47 protein in apost-treatment biological sample taken from the animal,

d. comparing the pre-treatment and post-treatment levels of LRG-47protein in the respective biological samples, and

e. determining that treatment is effective if the post-treatment levelof LRG-47 is significantly lower than the pre-treatment level.

The method includes further step f. if the treatment is not effective:if the difference between the pre-treatment and post-treatment levels ofLRG-47 protein is not significantly different, then increasing theamount or frequency of administration of the antisense or siRNA untilthe post-treatment level of LRG-47 is significantly lower than thepre-treatment level. These same basic methods can be used to treat anyautoimmune disease because all are associated with elevated levels ofactivated T cells.

Any compound that inhibits LRG-47 expression can be used to treat orprevent MS or an autoimmune disease.

Any method known in the art for measuring LRG-47 expression (measuringLRG-47 protein levels or mRNA, including using PCR and Northern blothybridization) in the biological sample can be used including thosedescribed herein. By “significantly lower” is meant that there is astatistically significant difference between pre- and post-treatmentlevels of LRG-47 protein or mRNA. LRG-47 can be measured in anybiological sample, preferably serum or cerebrospinal fluid (CSF), orblood using any method known in the art. Biopsy samples (for example ofskin and fibroblasts), if available, can also be analyzed. The siRNA orantisense compounds directed to LRG-47 DNA or mRNA can be formulatedinto a pharmaceutical carrier using any method known in the art, andadministered by any method known in the art.

The isolated antisense or siRNA nucleic acid molecules for use in theinvention comprise a nucleic acid molecule which is a complement of thepartial cDNA (confirm it is cDNA) sequence shown in SEQ ID NO:1,encoding human LRG-47, or a portion thereof. Antisense can also becomplementary to mRNA encoding LRG-47. A nucleic acid molecule which iscomplementary to a given nucleotide sequence is one which issufficiently complementary to the given nucleotide sequence that it canhybridize to the given nucleotide sequence thereby forming a stableduplex.

Antisense nucleic acid molecules, i.e., molecules which arecomplementary to a sense nucleic acid encoding a protein, e.g.,complementary to the coding strand of a double-stranded DNA molecule (orcDNA) or complementary to an mRNA sequence. Accordingly, an antisensenucleic acid can hydrogen bond to a sense nucleic acid. The antisensenucleic acid can be complementary to an entire LRG-47 coding strand, orto only a portion thereof, e.g., all or part of the protein codingregion (or open reading frame). An antisense nucleic acid molecule canbe antisense to a noncoding region of the coding strand of a nucleotidesequence encoding LRG-47. The noncoding regions (“5′ and 3′ untranslatedregions”) are the 5′ and 3′ sequences which flank the coding region andare not translated into amino acids.

Given the coding strand sequences encoding LRG-47 disclosed herein(e.g., SEQ ID NO:1), antisense nucleic acids of the invention can bedesigned according to the rules of Watson and Crick base pairing. Theantisense nucleic acid molecule can be complementary to the entirecoding region of LRG-47 mRNA, but more preferably is an oligonucleotidewhich is antisense to only a portion of the coding or noncoding regionof LRG-47 mRNA. For example, the antisense oligonucleotide can becomplementary to the region surrounding the translation start site ofLRG-47mRNA. An antisense oligonucleotide can be, for example, about 5,10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisensenucleic acid of the invention can be constructed using chemicalsynthesis and enzymatic ligation reactions using procedures known in theart. For example, an antisense nucleic acid (e.g., an antisenseoligonucleotide) can be chemically synthesized using naturally occurringnucleotides or variously modified nucleotides designed to increase thebiological stability of the molecules or to increase the physicalstability of the duplex formed between the antisense and sense nucleicacids, e.g., phosphorothioate derivatives and acridine substitutednucleotides can be used. Examples of modified nucleotides which can beused to generate the antisense nucleic acid include 5-fluorouracil,5-bromouracil, 5-chlorouracil, 5-hodouracil, hypoxanthine, xanthine,4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil,5-carboxymethylaminomethyl-2-thouridine,5-carboxymethylaminometh-yluracil, dihydrouracil,beta-D-galactosylqueosine, inosine, N6-isopentenyladenine,1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine,2-methylguanine, 3-methylcytosine, 5-metnylcytosine, N6-adenine,7-methylguanine, 5-methylaminomethyluracil,5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine,5′-methoxycarboxymethyluracil, 5-methoxyuracil,2-methylthio-N6-isopenten-yladenine, uracil-5-oxyacetic acid (v),wybutoxosine, pseudouracil, queosine, 2-thiocytosine,5-methyl-2-thiouracil, 2-thlouracil, 4-thiouracil, 5-methyluracil,uracil-5-oxyacetic acid methylester, uracil-5-cxyacetic acid (v),5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w,and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can beproduced biologically using an expression vector into which a nucleicacid has been subcloned in an antisense orientation (i.e., RNAtranscribed from the inserted nucleic acid will be of an antisenseorientation to a target nucleic acid of interest, described further inthe following subsection).

The antisense nucleic acid molecules of the invention are typicallyadministered to a subject or generated in situ such that they hybridizewith or bind to cellular mRNA and/or genomic DNA encoding the protein ofinterest to thereby inhibit expression of the protein, e.g., byinhibiting transcription and/or translation. The hybridization can be byconventional nucleotide complementary to form a stable duplex, or, forexample, in the case of an antisense nucleic acid molecule which bindsto DNA duplexes, through specific interactions in the major groove ofthe double helix. An example of a route of administration of antisensenucleic acid molecules of the invention include direct injection at atissue site. Alternatively, antisense nucleic acid molecules can bemodified to target selected cells and then administered systemically.For example, for systemic administration, antisense molecules can bemodified such that they specifically bind to receptors or antigensexpressed on a selected cell surface, e.g., by linking the antisensenucleic acid molecules to peptides or antibodies which bind to cellsurface receptors or antigens. The antisense nucleic acid molecules canalso be delivered to cells using the vectors described herein. Toachieve sufficient intracellular concentrations of the antisensemolecules, vector constructs in which the antisense nucleic acidmolecule is placed under the control of a strong pol II or pol IIIpromoter are preferred.

An antisense nucleic acid molecule of the invention can be analpha-anomeric nucleic acid molecule. An .alpha.-anomeric nucleic acidmolecule forms specific double-stranded hybrids with complementary RNAin which, contrary to the usual .beta.-units, the strands run parallelto each other (Gaultier et al. (1987) Nucleic Acids. Res. 15:6625-6641).The antisense nucleic acid molecule can also comprise a2′-o-methylribonucleotide (Inoue et al. (1987) Nucleic Acids Res.15:6131-6148) or a chimeric RNA-DNA analogue (Inoue et al. (1987) FEBSLett. 215:327-330). All of the methods described in the above articlesregarding antisense technology are incorporated herein by reference.

The invention also encompasses ribozymes. Ribozymes are catalytic RNAmolecules with ribonuclease activity which are capable of cleaving asingle-stranded nucleic acid, such as an mRNA, to which they have acomplementary region. Thus, ribozymes (e.g., hammerhead ribozymes(described in Haselhoff and Gerlach (1988) Nature 334:585-591)) can beused to catalytically cleave LRG-47mRNA transcripts thereby inhibittranslation of LRG-47mRNA. A ribozyme having specificity for anLRG-47-encoding nucleic acid can be designed based upon the nucleotidesequence of a LRG-47cDNA disclosed herein. For example, a derivative ofa Tetrahymena L-19 IVS RNA can be constructed in which the nucleotidesequence of the active site is complementary to the nucleotide sequenceto be cleaved in an LRG-47-encoding mRNA. See, e.g., Cech et al. U.S.Pat. No. 4,987,071; and Cech et al. U.S. Pat. No. 5,116,742.Alternatively, LRG-47mRNA can be used to select a catalytic RNA having aspecific ribonuclease activity from a pool of RNA molecules. See, e.g.,Bartel and Szostak (1993) Science 261:1411-1418, incorporated herein byreference.

As used herein, the term “nucleic acid” refers to both RNA and DNA,including cDNA, genomic DNA, and synthetic (e.g., chemicallysynthesized) DNA. The nucleic acid can be double-stranded orsingle-stranded (i.e., a sense or an antisense single strand). As usedherein, “isolated nucleic acid” refers to a nucleic acid that isseparated from other nucleic acid molecules that are present in amammalian genome, including nucleic acids that normally flank one orboth sides of the nucleic acid in a mammalian genome (e.g., nucleicacids that flank an ARPKD gene). The term “isolated” as used herein withrespect to nucleic acids also includes any non-naturally-occurringnucleic acid sequence, since such non-naturally-occurring sequences arenot found in nature and do not have immediately contiguous sequences ina naturally-occurring genome.

An isolated nucleic acid can be, for example, a DNA molecule, providedone of the nucleic acid sequences normally found immediately flankingthat DNA molecule in a naturally-occurring genome is removed or absent.Thus, an isolated nucleic acid includes, without limitation, a DNAmolecule that exists as a separate molecule (e.g., a chemicallysynthesized nucleic acid, or a cDNA or genomic DNA fragment produced byPCR or restriction endonuclease treatment) independent of othersequences as well as DNA that is incorporated into a vector, anautonomously replicating plasmid, a virus (e.g., a retrovirus,lentivirus, adenovirus, or herpes virus), or into the genomic DNA of aprokaryote or eukaryote. In addition, an isolated nucleic acid caninclude an engineered nucleic acid such as a DNA molecule that is partof a hybrid or fusion nucleic acid. A nucleic acid existing amonghundreds to millions of other nucleic acids within, for example, cDNAlibraries or genomic libraries, or gel slices containing a genomic DNArestriction digest, is not to be considered an isolated nucleic acid.

Small Interfering RNA

A person of skill in the art can make any number of different siRNAsbased on the partial human cDNA gene sequence SEQ ID NO: 1 for LRG-47.When the full gene sequence becomes available, other siRNAs can bedesigned to block expression, i.e. translation of LRG-47 using routinemethods known in the art.

Patent Application 20040023390 (the entire contents of which are herebyincorporated by reference as if fully set forth herein) teaches thatdouble-stranded RNA (dsRNA) can induce sequence-specificposttranscriptional gene silencing in many organisms by a process knownas RNA interference (RNAi). However, in mammalian cells, dsRNA that is30 base pairs or longer can induce sequence-nonspecific responses thattrigger a shut-down of protein synthesis and even cell death throughapoptosis. Recent work shows that RNA fragments are thesequence-specific mediators of RNAi (Elbashir et al., 2001).Interference of gene expression by these small interfering RNA (siRNA)is now recognized as a naturally occurring strategy for silencing genesin C. elegans, Drosophila, plants, and in mouse embryonic stem cells,oocytes and early embryos (Cogoni et al., 1994; Baulcombe, 1996;Kennerdell, 1998; Timmons, 1998; Waterhouse et al., 1998; Wianny andZernicka-Goetz, 2000; Yang et al., 2001; Svoboda et al., 2000).

In mammalian cell culture, a siRNA-mediated reduction in gene expressionhas been accomplished by transfecting cells with synthetic RNA nucleicacids (Caplan et al., 2001; Elbashir et al., 2001). The 20040023390application, the entire contents of which are hereby incorporated byreference as if fully set forth herein, provides methods using a viralvector containing an expression cassette containing a pol II promoteroperably-linked to a nucleic acid sequence encoding a small interferingRNA molecule (siRNA) targeted against a gene of interest.

As used herein RNAi is the process of RNA interference. A typical mRNAproduces approximately 5,000 copies of a protein. RNAi is a process thatinterferes with or significantly reduces the number of protein copiesmade by an mRNA. For example, a double-stranded short interfering RNA(siRNA) molecule is engineered to complement and match theprotein-encoding nucleotide sequence of the target mRNA to be interferedwith. Following intracellular delivery, the siRNA molecule associateswith an RNA-induced silencing complex (RISC). The siRNA-associated RISCbinds the target mRNA (such as mRNA encoding LRG-47) through abase-pairing interaction and degrades it. The RISC remains capable ofdegrading additional copies of the targeted mRNA. Other forms of RNA canbe used such as short hairpin RNA and longer RNA molecules. Longermolecules cause cell death, for example by instigating apoptosis andinducing an interferon response. Cell death was the major hurdle toachieving RNAi in mammals because dsRNAs longer than 30 nucleotidesactivated defense mechanisms that resulted in non-specific degradationof RNA transcripts and a general shutdown of the host cell. Using fromabout 20 to about 29 nucleotide siRNAs to mediate gene-specificsuppression in mammalian cells has apparently overcome this obstacle.These siRNAs are long enough to cause gene suppression but not of alength that induces an interferon response.

Methods for Diagnosing MS\

Certain other embodiments are also directed to a method for diagnosingmultiple sclerosis in an animal preferably a human by assessing thelevel of human LRG-47 protein in any biological sample taken from theanimal, preferably serum, cerebrospinal fluid (CSF) or blood, but alsoin a tissue sample including fibroblasts or skin.

A method for diagnosing a patient having MS or at risk of developing MSor having MS, involves the steps of

a. determining a level of LRG-47 protein in a biological sample takenfrom the patient and in a corresponding control sample taken from acontrol subject that is not affected with multiple sclerosis,b. comparing the level of LRG-47 protein in the two biological samplesandc. concluding that the patient has or is at risk of developing multiplesclerosis if the LRG-47 level in the patient sample is significantlyhigher than the level in the control sample. This method can also beused to detect an autoimmune disease associated with elevated T cells.It is hoped that early detection of changes in LRG-47 expression willfacilitate early diagnosis and treatment.

If blood leukocytes or other cells are used in the assay then one canmonitor either LRG-47 protein or mRNa levels to make the diagnosis. Ifthe difference between the control and patient levels is very high, andthe patient displays other indicia of MS, this test can confirm adiagnosis of MS. Another embodiment is directed to a method formonitoring the level of advancement or progression of MS in a patient bydetermining changes over time in the LRG-47 protein levels, preferablywith regular assessments even during periods of apparent remission. Ifthe level increases over time then the diseases is progressing orbecoming more advanced. Monitoring the level of LRG-47 or LRG-47 mRNA ina patient sample can also be sued to measure the efficacy of MS therapy;if the levels are going down the therapy is effective. The level ofLRG-47 may rise before any symptoms of MS have noticeably worsened,making it possible to intervene early in treatment to prevent a seriousrelapse.

Other embodiments are directed to a diagnostic kit for determining thelevel of LRG-47 in a biological sample that includes: a) a vessel orvessels for receiving a blood/serum or CSF or cell sample from thesubject; b) an agent that specifically detects LRG-47 protein oramplifies LRG-47 mRNA; and c) printed instructions for detecting theLRG-47 protein or the amplified LRG-47 mRNA in the sample. The agent canbe a primary anti-LRG-47 antibody for quantifying LRG-47, and asecondary antibody for detecting binding of the primary antibody canalso be included in the kit. In another embodiment the antibody isalready labeled for easy detection. Any antibody described herein or newantibodies that become known that target LRG-47 can be used, preferablythose that target human LRG-47.

Pharmaceutical Preparations

The present invention also includes pharmaceutical compositions andformulations which include the antibodies and antisense compounds of theinvention that are administered to treat or prevent multiple sclerosis.The pharmaceutical compositions of the present invention may beadministered in a number of ways depending upon whether local orsystemic treatment is desired and upon the area to be treated. Thepreferred rout of administration is intravenous, but administration canalso parenteral including intra-arterial, subcutaneous, intraperitonealor intramuscular injection or infusion; or intracranial, e.g.,intrathecal or intraventricular, administration.

Pharmaceutical compositions of the present invention contain thetherapeutic agent (antibodies or antisense nucleic acids or si RNA thatreduce the expression of LRG-47) in an amount sufficient to prevent ortreat MS or an autoimmune disease in a subject. The therapeutic agentcan be formulated with an acceptable carrier using methods well known inthe art. The actual amount of therapeutic agent will necessarily varyaccording to the particular formulation, route of administration, anddosage of the pharmaceutical composition, the specific nature of thecondition to be treated, and possibly the individual subject. The dosagefor the pharmaceutical compositions of the present invention can rangebroadly depending upon the desired effects, the therapeutic indication,the route of administration, regime, and purity and activity of thecomposition.

Pharmaceutical compositions of the present invention are suitable foradministration to a subject in need of prophylaxis or therapy of MS oran autoimmune disease. The subject is preferably a human but can benon-human as well. A suitable subject can be an individual who issuspected of having, has been diagnosed as having, or is at risk ofdeveloping MS or an autoimmune disease, and like conditions as can bedetermined by one knowledgeable in the art.

Techniques for formulation and administration can be found in“Remington: The Science and Practice of Pharmacy” (20.sup.th edition,Gennaro (ed.) and Gennaro, Lippincott, Williams & Wilkins, 2000),incorporated herein by reference. The pharmaceutical compositions of thepresent invention can be administered to the subject by a medicaldevice, such as, but not limited to, catheters, balloons, implantabledevices, biodegradable implants, prostheses, grafts, sutures, patches,shunts, or stents.

The invention has been described in the foregoing specification withreference to specific embodiments. It will however be evident thatvarious modifications and changes may be made to the embodiments withoutdeparting from the broader spirit and scope of the invention. Thespecification and drawings are to be regarded in an illustrative ratherthan a restrictive sense.

Examples

Mice.

LRG-47 knockout mice (LRG-47^(−/−)) were generated as describedpreviously [9]. Mice were backcrossed into the B10PL background (N=10generations). Wild-type (WT) littermates (in B10PL) served as controls.

Induction of EAE.

EAE was induced as previously described [10] using a protocol approvedby Columbia University's Institutional Animal Care and Use Committee.Induction of EAE using the MBP model was performed by immunizing B10PLmice subcutaneously with 1-9NAc myelin basic protein (MBP) in completeFreund's adjuvant (CFA) on day 0. For adoptive transfer of EAE, anactivated encephalitogenic CD4 Th1 clone (1AE10; 10×10⁶ cells/animal)was administered intravenously to sublethally irradiated (350 R) mice.Pertussis toxin (100 μg/mouse) was given via the tail vein on days 1 and3. Clinical symptoms were scored from 1 to 5 as described [10].

Isolation of Mononuclear Cell from the CNS.

To analyze cellular infiltrates in the central nerve system (CNS), micewere deeply anesthetized and perfused intracardially with PBS (30 ml).Brain and spinal cord were chopped into pieces and digested for 45 minat 37° C. in Hanks balanced salt solution containing 0.2 units ofliberase R1 (Roche) and 50 μg⁻¹ DNase I. Softened tissue fragments wereforced through a 40 μm cell strainer, and homogenates were resuspendedin 70% Percoll (Sigma) and overlaid with 30% Percoll. Gradients werecentrifuged at 2000×g for 30 min. Mononuclear cells in the CNS werecollected from the Percoll interface.

Flow Cytometry.

Cells were washed with FACS buffer [PBS containing 0.1% (w/v) sodiumazide and 2% (v/v) fetal calf serum] and preincubated with CD16/CD32monoclonal antibody (clone 2.4G2, Pharmingen) for 15 min at 4° C. toblock non-specific binding to Fc receptors. Fluorochrome-conjugatedmonoclonal antibodies (rat anti-mouse CD4-PerCP, rat anti-mouse CD44-PEand appropriate isotype controls) were purchased from Pharmingen. Afterincubation, cells were washed twice with FACS buffer and data wereacquired on a FACSCalibur flow cytometer (Becton Dickison, FranklinLakes, N.J.), analyzed by using FLOWJO software (Treestar, San Carlos,Calif.).

Proliferation Assays.

For T-cell proliferation, cells isolated from spleens and lymph nodeswere cultured in the serum free medium with 1-9NAc MBP (2.5 μg/ml) for72 hours. ³H-thymindine (1 μCi/well) was added 16 hours prior toharvesting. For the in vivo 5-Bromo-2′-Deoxyuridine (BrdU, Sigma) uptakeassay, mice were injected intraperitoneally with 1 mg of BrdU twice ondays 13 and 14 during the course of EAE. CNS mononuclear cells wereisolated and stained with anti-CD4-PerCP (Pharmingen). BrdU staining wasperformed according to instructions of the manufacturer (Pharmingen).BrdU incorporation was analyzed on gated CD4⁺ T cells.

1AE10 Cell Labeling with Carboxyfluorescein Succinimidyl Ester (CFSE)and Assessment of Proliferation.

MBP-specific CD4 T-cell clones (1AE10) were incubated with 2 μM CFSE(Molecular Probes) in T-cell medium for 15 min at 37° C. CFSE stainingwas stopped by addition of excess medium, and cells were washed twice inmedium. CFSE-labeled 1AE10 cells (1×10⁶/ml) were cultured with wild-typespleen cells, the latter as antigen presenting cells (APCs)(2×10⁶/ml),in T-cell medium containing MBP₁₋₉ (2.5 μg/ml) and with/withoutanti-LRG-47 antibody or non-immune IgG. Cells were harvested at the timepoints indicated, and stained with anti-CD4-PerCP and anti-CD44-PE IgG.The CFSE fluorescence profile was analyzed on gated CD4⁺ T-cells.

Assays for Apoptosis.

Apoptosis was measured in vitro using three different methods: (i) TheAnnexin V assay was used to detect cells in early stages of apoptosis.PI (propidium iodide) staining was detected in the dead cells. 1AE10,splenic and CNS cells were stained with anti-CD4-allophycocyanin andanti-CD44-PE IgG, and resuspended in annexin binding buffer. Cells werestained for 15 min with 5 μl of FITC-labeled annexin V (PharMingen) and10 μl of PI at room temperature in the dark Analysis was performed byflow cytometry within 1 hr. (ii) In situ detection of apoptotic cellswas performed on MBP-activated CD4 T-cells cultured on chamber slidesusing the in situ Cell Death Detection Kit (Roche, Germany). Briefly,air-dried cell samples were fixed with a freshly prepared fixationsolution for 1 h at 15-25° C., and then incubated in permeabilizationsolution for 2 min on ice. TUNEL-positive cells were detected accordingto the manufacturer's instructions (Roche, Calif.). The percentage ofTUNEL-positive cells is described as the percentage of the number ofTUNEL-positive cells divided by the total number of cells in each field.

Quantitative Real-Time PCR.

Total RNA was extracted from 1AE10 cells, lymph nodes and spinal cordusing the TRIzol method (Invitrogen Life Technologies) according to themanufacturer's protocol. cDNA synthesis was performed using RandomHexamers primers and the TaqMan Reverse Transcription kit (AppliedBiosystems). Samples were subjected to real-time PCR analysis on an ABIPrism 7700 Sequence Detection System under standard conditions. RelativemRNA abundance was normalized against GAPDH (the endogenous control).The primers and probe for LRG were designed using Primer Expresssoftware (Applied Biosystems) and purchased from Applied Biosystems(5′-TGG CAA TGG CAT GTC ATC TT-3′ (SEQ ID NO: 9), reverse primer 5′-AGTACT CAG TCC GCG TCT TCG T-3′ (SEQ ID NO: 10), and probe 6FAMACT TCG AGTCAT CGG CMGBNFQ (SEQ ID NO: 11)).

Northern Blotting.

Samples for Northern blotting were collected from 1AE10 cells orMBP-immunized wild-type mice. Total RNA was isolated using Trizol(Invitrogen). For each sample, 5-10 μg of total RNA was electrophoresedthrough 1% agarose-6% formaldehyde gels. RNAs were transferred to HybondN+ membranes and hybridized with the ³²P-labeled mouse LRG-47 probes.

ELISA for the Cytokine Detection.

CD4 T-cells were isolated from MBP-immunized mouse spleen/lymph nodesand purified using magnetic beads conjugated with anti-CD4 mAb and amagnetic column (Milten Biotec). 1AE10 cells or CD4 T-cells werecultured in T-cell medium (Click's medium with 10% FCS, 0.01M Hepes,5×10⁻⁵M 2-ME, 8 mM L-glutamine, and antibiotics) at 2×10⁶/ml (0.5ml/well) in 48-well plates with MBP (2.5 μg/ml), and irradiated spleniccells (4×10⁶/ml) as APCs. Supernatants were collected at the time pointsindicated. Analyses of murine IFNγ were performed on both supernatantsand serum samples, collected at day 14 post induction of EAE usingcommercially available ELISA kits (R&D Systems, MN). Sensitivity of theassays was <2 pg/ml for IFNγ.

Histology and Immunostaining.

Paraffin-embedded sections were stained with H&E and the area occupiedby nuclei per high-power field was evaluated using the Universal ImagingSystem. To localize LRG-47 antigen in spinal cord, double immunostainingwith anti-LRG-47 and anti-CD4 or CD11b IgG was performed. Cryopreservedspinal cord sections were fixed with 4% paraformaldehyde in PBS for 30min. Slides were permeabilized and blocked in PBS containing 5% horseserum and 0.2% saponin for 60 min. They were then incubated with goatanti-LRG-47 IgG (A-19, Santa Cruze, Calif.), rat anti-CD4, or ratanti-CD11b mAbs (BD Pharmingen) followed by secondary antibodies (donkeyanti-goat IgG conjugated-FITC and rabbit anti-rat IgG conjugated-TRITC,Sigma). Sections were examined by confocal microscopy.

To localize LRG-47 in MBP-stimulated 1AE10 cells as compared tonon-stimulated 1AE10 cells, 1AE10 cells were exposed to MBP (5 μg/ml)for 4 hours, and then were fixed in 4% paraformaldehyde alone or plus0.1% NP-40 for 30 min. Sites of LRG-47 were detected using goatanti-LRG-47 IgG (1:300) followed by donkey anti-goat IgG conjugated withFITC (1:100). To determine the localization of LRG-47 in Golgiapparatus, 1AE10 cells were co-stained with GRASP65 IgG antibody, amaker for the Golgi apparatus (Abcam, Cambridge, Mass.), followed bysheep anti-rabbit IgG conjugated with TRITC (1:200, Sigma, CA). Sectionswere examined by confocal microscopy.

Statistic Analysis.

When two groups were compared, a two-tailed student t-test was used.When multiple groups were compared, analysis of variance (ANOVA) will beemployed Fish's t-test was used for post-hoc comparisons. Values ofp<0.05 was considered statistically significant.

SiRNA

After stimulated with MBP (5 μ/ml) for 48 hour, 1AE10 T cells weretransfected with siRNA targeted to mouse LRG-47 (sense sequence:5′-GGUUACCUGAGGUCAGUAGtt-3′ (SEQ ID NO: 5), antisense sequence:5′-CUACUGACCUCAGGUAACCtg-3′) (SEQ ID NO: 6)) using siPORT Amine (Ambion)for additional 24. Levels of LRG-47 mRNA in cells were determined byreal-time quantitative PCR and RT-PCR.

Multiple Sclerosis Patient

The spinal cord tissues were obtained from the Human Brain and SpinalFluid Resource Center, VAMC, Los Angeles, Calif. 90073.

Neuropathology HSB# Age Gender diagnosis Coronal Structure 2696 86 FMultiple Sclerosis CXL-1 Cervical Cord 2771 64 F Multiple sclerosisCXL-1 Cervical Cord 2800 64 F Multiple Sclerosis CXL-1 Cervical Cord2932 57 F Multiple Sclerosis CXL-1 Cervical Cord 2935 79 F MultipleSclerosis CXL-1 Cervical Cord 3175 54 F Normal CXL-1 Cervical Cord 321679 M Normal Aging CXL-1 Cervical Cord 3348 76 F Normal CXL-1 CervicalCord 3371 52 M Normal CXL-1 Cervical Cord 2348 53 M Normal CXL-1Cervical Cord

BC128168 Homo sapiens gi: 118764008; Incorporated herein by referenceSEQ ID NO: 1 Partial cDNA sequence (sense strand) for LRG-47atggaagcca tgaatgttga gaaagcctca gcagatgggaacttgccaga ggtgatctct aacatcaagg agactctgaagatagtgtcc aggacaccag ttaacatcac tatggcaggggactctggca atgggatgtc caccttcatc agtgcccttcgaaacacagg acatgagggt aaggcctcac ctcctactgagctggtaaaa gctacccaaa gatgtgcctc ctatttctcttcccactttt caaatgtggt gttgtgggac ctgcctggcacagggtctgc caccacaacc ctggagaact acctgatggaaatgcagttc aaccggtatg acttcatcat ggttgcatctgcacaattca gcatgaatca tgtgatgctt gccaaaaccgctgaggacat gggaaagaag ttctacattg tctggaccaagctagacatg gacctcagca caggtgccct cccagaagtgcagctactgc agatcagaga aaatgtcctg gaaaatctcc agaaggagcg ggtatgtgaa tactaaBC128168 Homo sapiens gi: 118764008 Incorporated herein by referenceSEQ ID NO 2 AMINO ACID SEQUENCE for LRG-47MNVEKASADGNLPEVISNIKETLKIVSRTPVNITMAGDSGNGMSTFISALRNTGHEGKASPPTELVKATQRCASYFSSHFSNVVLWDLPGTGSATTTLENYLMEMQFNRYDFIMVASAQFSMNHVMLAKTAEDMGKKFYIVWTKLDMDLSTGALPEVQLLQIRENVLENLQKERVCEY U19119 Mus musculus G-[gi: 633753]Incorporated herein by reference SEQ ID NO 3 DNA SEQUENCE FOR for LRG-47gcaaggtctg ctcgaagacc agaagctgaa agaaaatccacgcgatcaga cctcctcttg gttcgtctcc tctcagaaggactccagacc tctgcatctc atctctcaac atccgggtctatattccagt tttggatctc tacataggga acttctgccggaggacagca acgtttttgt cctaggaaga aaggggtgacgttccaggaa ggccactaac atcgaatcac acataataactcctctggat cagggtttga ggagtattaa gtgagataaggcattcgaag gaaccaactc agattcacag acagaggacctgtgtgctta aagtctaaga gtggaggaag aacctgaggagcggcttcct cagagaccct aataaaacca gagagcctcaccagggagct gaaaggtcca cagacagcgt cactcggatcttatcatgaa accatcacac agttcctgcg aggctgctccactactcccc aacatggcag agacccatta tgctcccctgagctcagcct tcccctttgt cacgtcatac caaacaggctccagcaggtt acctgaggtc agtaggagca ccgaaagagctttaagagaa ggaaaactac tggaactggt ctacggaatcaaggagactg tggcaacatt gtcccagatt ccagtgagcatctttgtgac tggggactct ggcaatggca tgtcatctttcatcaatgca cttcgagtca tcggccatga tgaagatgcctcggctccca ctggggtggt gaggaccacg aagacgcggactgagtactc ttcatcccac tttcccaatg tggtgctgtgggacttacct ggattggggg ccacagccca aaccgtagaggactatgtgg aagagatgaa atttagcaca tgtgacttattcatcatcat tgcctctgag cagttcagct cgaatcatgtgaagctgtcc aaaattatcc agagcatggg aaagaggttctatattgtct ggaccaagct ggacagggac ctcagcaccagtgtcctatc agaggtccgg ctcctacaga atatccaggagaatatccga gagaatctgc agaaggagaa agtgaagtacccccccgtgt tcctggtatc cagtctagac cctttactatatgacttccc gaagcttagg gacacacttc ataaagatctctccaacatc aggtgctgtg aacccttaaa gaccctttatggcacttatg agaagatcgt tggtgataaa gtagcagtctggaagcagag aatagccaac gagtccttga agaattctctcggtgtcaga gatgatgaca acatgggcga gtgtctgaaagtgtaccgac tgatatttgg tgtagatgac gaatcagttcagcaggtagc ccagagtatg gggacagtag tcatggagtacaaggacaac atgaagtccc aaaactttta tactctccgcagagaggact ggaaactgag gctgatgaca tgtgcaattgtgaatgcatt cttccgtttg ttgagatttc tcccatgcgtatgctgctgt ttaagacgct tgagacataa acgcatgcttttcttagttg cccaggacac caagaacatc ctagagaaaatcctgaggga ctccatcttc cctccgcaga tctagtataagggcagcctg gtacccttct tcttccacag aagccaggttaccttagatc tctttcctag atccctattt ctccaccagaaatcaagaga tacaaaaatg cttcctgtaa gggttttagattctctgaga ggagttaaaa tcactcatct cccctgtctcgattctaatg cattgttcca ctgagggaca gggacaagtagtgattaaaa ttcattgacc atgattctta gatttggaatatagaaattt tgtttttggg ctggagagat ggcttagcagttaagaacac caactgcttt tccgaaggtc atgagttcaaatcccagcaa ccacgtgatg gctcacaacc atccgtagtgagatctgatg ccctcttctg agatgtctga agacagctacagtgtactta catataataa ataaataaat aaataaataaataaataaat ctttgggaaa aaaattagaa attttgttttcagctattaa atgtgatata tgtccaaatc aattttcctctgaaacaata aagtcggttc ctcttca U19119 Mus musculus G-[gi: 633753]Incorporated herein by reference SEQ ID NO: 4AMINO ACID SEQUENCE FOR LRG-47MKPSHSSCEAAPLLPNMAETHYAPLSSAFPFVTSYQTGSSRLPEVSRSTERALREGKLLELVYGIKETVATLSQIPVSIFVTGDSGNGMSSFINALRVIGHDEDASAPTGVVRTTKTRTEYSSSHFPNVVLWDLPGLGATAQTVEDYVEEMKFSTCDLFIIIASEQFSSNHVKLSKIIQSMGKRFYIVWTKLDRDLSTSVLSEVRLLQNIQENIRENLQKEKVKYPPVFLVSSLDPLLYDFPKLRDTLHKDLSNIRCCEPLKTLYGTYEKIVGDKVAVWKQRIANESLKNSLGVRDDDNMGECLKVYRLIFGVDDESVQQVAQSMGTVVMEYKDNMKSQNFYTLRREDWKLRLMTCAIVNAFFRLLRFLPCVCCCLRRLRHKRMLFLVAQDTKNILEKIL RDSIFPPQI

REFERENCES

-   1. Refaeli, Y., L. Van Parijs, S. I. Alexander, and A. K. Abbas,    Interferon gamma is required for activation-induced death of T    lymphocytes. J Exp Med, 2002. 196(7): p. 999-1005.-   2. Dalton, D. K., L. Haynes, C. Q. Chu, S. L. Swain, and S. Wittmer,    Interferon gamma eliminates responding CD4 T cells during    mycobacterial infection by inducing apoptosis of activated CD4 T    cells. J Exp Med, 2000. 192(1): p. 117-22.-   3. Chu, C. Q., S. Wittmer, and D. K. Dalton, Failure to suppress the    expansion of the activated CD4 T cell population in interferon    gamma-deficient mice leads to exacerbation of experimental    autoimmune encephalomyelitis. J Exp Med, 2000. 192(1): p. 123-8.-   4. Taylor, G. A., C. G. Feng, and A. Sher, p47 GTPases: regulators    of immunity to intracellular pathogens. Nat Rev Immunol, 2004.    4(2): p. 100-9.-   5. Taylor, G. A., M. Jeffers, D. A. Largaespada, N. A.    Jenkins, N. G. Copeland, and G. F. Woude, Identification of a novel    GTPase, the inducibly expressed GTPase, that accumulates in response    to interferon gamma. J Biol Chem, 1996. 271(34): p. 20399-405.-   6. MacMicking, J. D., IFN-inducible GTPases and immunity to    intracellular pathogens. Trends Immunol, 2004. 25(11): p. 601-9.-   7. Santiago, H. C., C. G. Feng, A. Bafica, E. Roffe, R. M.    Arantes, A. Cheever, G. Taylor, L. Q. Vierira, J. Aliberti, R. T.    Gazzinelli, and A. Sher, Mice Deficient in LRG-47 Display Enhanced    Susceptibility to Trypanosoma cruzi Infection Associated with    Defective Hemopoiesis and Intracellular Control of Parasite Growth.    J Immunol, 2005. 175(12): p. 8165-72.-   8. Gutierrez, M. G., S. S. Master, S. B. Singh, G. A. Taylor, M. I.    Colombo, and V. Deretic, Autophagy is a defense mechanism inhibiting    BCG and Mycobacterium tuberculosis survival in infected macrophages.    Cell, 2004. 119(6): p. 753-66.-   9. MacMicking, J. D., G. A. Taylor, and J. D. McKinney, Immune    control of tuberculosis by IFN-gamma-inducible LRG-47.    Science, 2003. 302(5645): p. 654-9.-   10. Yan, S. S., Z. Y. Wu, H. P. Zhang, G. Furtado, X. Chen, S. F.    Yan, A. M. Schmidt, C. Brown, A. Stern, J. LaFaille, L. Chess, D. M.    Stern, and H. Jiang, Suppression of experimental autoimmune    encephalomyelitis by selective blockade of encephalitogenic T-cell    infiltration of the central nervous system. Nat Med, 2003. 9(3): p.    287-93.-   11. Martens, S., K. Sabel, R. Lange, R. Uthaiah, E. Wolf, and J. C.    Howard, Mechanisms regulating the positioning of mouse p47    resistance GTPases LRG-47 and IIGP1 on cellular membranes:    retargeting to plasma membrane induced by phagocytosis. J    Immunol, 2004. 173(4): p. 2594-606.-   12. Butcher, B. A., R. I. Greene, S. C. Henry, K. L.    Annecharico, J. B. Weinberg, E. Y. Denkers, A. Sher, and G. A.    Taylor, p47 GTPases regulate Toxoplasma gondii survival in activated    macrophages. Infect Immun, 2005. 73(6): p. 3278-86.-   13. MacMicking, J. D., Immune control of phagosomal bacteria by p47    GTPases. Curr Opin Microbiol, 2005. 8(1): p. 74-82.-   14. Feng, C. G., C. M. Collazo-Custodio, M. Eckhaus, S. Hieny, Y.    Belkaid, K. Elkins, D. Jankovic, G. A. Taylor, and A. Sher, Mice    deficient in LRG-47 display increased susceptibility to    mycobacterial infection associated with the induction of    lymphopenia. J Immunol, 2004. 172(2): p. 1163-8.-   15. Sorace, J. M., R. J. Johnson, D. L. Howard, and B. E. Drysdale,    Identification of an endotoxin and IFN-inducible cDNA: possible    identification of a novel protein family. J Leukoc Biol, 1995.    58(4): p. 477-84.-   16. Collazo, C. M., G. S. Yap, G. D. Sempowski, K. C. Lusby, L.    Tessarollo, G. F. Woude, A. Sher, and G. A. Taylor, Inactivation of    LRG-47 and IRG-47 reveals a family of interferon gamma-inducible    genes with essential, pathogen-specific roles in resistance to    infection. J Exp Med, 2001. 194(2): p. 181-8.-   17. O'Connor, R. A., S. Wittmer, and D. K. Dalton, Infection-induced    apoptosis deletes bystander CD4+ T cells: a mechanism for    suppression of autoimmunity during BCG infection. J Autoimmun, 2005.    24(2): p. 93-100.-   18. Zhang, Y., J. N. Blattman, N. J. Kennedy, J. Duong, T.    Nguyen, Y. Wang, R. J. Davis, P. D. Greenberg, R. A. Flavell, and C.    Dong, Regulation of innate and adaptive immune responses by MAP    kinase phosphatase 5. Nature, 2004. 430(7001): p. 793-7.

1.-25. (canceled)
 26. A method for treating or preventing multiplesclerosis in a patient, comprising administering a therapeuticallyeffective amount of an isolated anti-LRG-47 antibody or biologicallyactive fragment or variant thereof or a compound that reduces LRG-47expression.
 27. The method of claim 26, wherein the isolated antibody ispolyclonal anti-human LRG-47 antibody 138AB or a biologically activefragment or variant thereof.
 28. The method of claim 26, wherein theisolated anti-LRG-47 antibody is a humanized antibody selected from thegroup comprising LRG-47 (A-19) antibody, LRG-47 (M-95) antibody, LRG-47(M-16) antibody, and LRG-47 (P-20) antibody, or biologically activefragment or variant thereof.
 29. The method of claim 26, wherein theisolated antibody is a monoclonal, polyclonal, chimeric, humanized orbispecific antibody.
 30. The method of claim 26, wherein the compoundthat reduces LRG-47 expression is an antisense nucleic acid or siRNA.31. The method of claim 30, wherein the antisense nucleic acid issufficiently complementary to the human gene or mRNA encoding LRG-47 tohybridize to it thereby reducing expression of LRG-47.
 32. The method ofclaim 31, wherein the human gene encoding LRG-47 is identified by SEQ IDNO:
 1. 33. The method of claim 30, wherein the siRNA comprises SEQ IDNOs: 5 and
 6. 34. A method for treating or preventing multiple sclerosisin a patient, comprising: a. determining a pre-treatment level of humanLRG-47 protein in a pre-treatment biological sample taken from thepatient, b. administering an amount of a compound that reduces humanLRG-47 expression levels in patient cells, c. determining apost-treatment level of human LRG-47 protein in a post-treatmentbiological sample taken from the patient, d. comparing the pre-treatmentand post-treatment levels of LRG-47 protein in the respective biologicalsamples, and e. determining that treatment is effective if thepost-treatment level of human LRG-47 is significantly lower than thepre-treatment level.
 35. The method of claim 34, further comprising: f.if the difference between the pre-treatment and post-treatment levels ofhuman LRG-47 is not significantly different, then increasing the amountor frequency of administration of the compound until the post-treatmentlevel of human LRG-47 is significantly lower than the pre-treatmentlevel.
 36. The method of claim 34, wherein the compound is an antisensenucleic acid or siRNA.
 37. The method of claim 36, wherein the antisensenucleic acid is sufficiently complementary to the human gene or mRNAencoding LRG-47 to hybridize to it thereby reducing expression of theLRG-47 protein.
 38. The method of claim 37, wherein the human geneencoding LRG-47 is identified by SEQ ID NO:
 1. 39. The method of claim34, wherein the siRNA comprises SEQ ID NOs: 5 and
 6. 40. The method ofclaim 34, wherein the biological sample is a member selected from thegroup comprising a nerve sample, serum, blood, plasma, cerebral spinalfluid, fibroblasts, leukocytes, skin, and urine.
 41. The anti-humanLRG-47 antibody 138AB or a biologically active fragment or variantthereof.
 42. A pharmaceutical composition comprising an isolatedanti-LRG-47 antibody that is a member selected from the group comprisingthe anti-human LRG-47 antibody 138AB, humanized LRG-47 (A-19) antibody,humanized LRG-47 (M-95) antibody, humanized LRG-47 (M-16) antibody, andhumanized LRG-47 (P-20) antibody or a biologically active fragment orvariant thereof.
 43. A method for diagnosing a patient who is at risk ofdeveloping multiple sclerosis, comprising a. determining the level ofhuman LRG-47 protein in a biological sample taken from the patient andin a corresponding sample taken from a control subject that is notaffected with multiple sclerosis, b. comparing the level of human LRG-47protein in the biological samples and forming a diagnosis that thepatient is at risk of developing multiple sclerosis if the level ofhuman LRG-47 protein in the patient sample is significantly higher thanthe level of human LRG-47 protein in the control sample.
 44. The methodof claim 43, further comprising the step of c. determining that thepatient has multiple sclerosis if the patient shows other objective orsubjective indicia of multiple sclerosis.
 45. The method as in claim 43,wherein the biological sample is a member selected from the groupcomprising a nerve sample, serum, blood, plasma, cerebral spinal fluid,fibroblasts, leukocytes, skin, and urine.
 46. The method as in claim 45,wherein the biological sample is a member selected from the groupcomprising a nerve sample, serum, blood, plasma, cerebral spinal fluid,fibroblasts, leukocytes, skin, and urine.
 47. The method as in claim 42,wherein the anti-human LRG-47 antibody 138AB is humanized.